WO2023038154A1 - Fibre polypeptidique artificielle de grand diamètre, son procédé de fabrication et adhésif - Google Patents

Fibre polypeptidique artificielle de grand diamètre, son procédé de fabrication et adhésif Download PDF

Info

Publication number
WO2023038154A1
WO2023038154A1 PCT/JP2022/034270 JP2022034270W WO2023038154A1 WO 2023038154 A1 WO2023038154 A1 WO 2023038154A1 JP 2022034270 W JP2022034270 W JP 2022034270W WO 2023038154 A1 WO2023038154 A1 WO 2023038154A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
fibroin
artificial
sequence
Prior art date
Application number
PCT/JP2022/034270
Other languages
English (en)
Japanese (ja)
Inventor
徹 高橋
廉 伊藤
聡 石原
聡 小池田
Original Assignee
Ｓｐｉｂｅｒ株式会社
天野エンザイム株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ｓｐｉｂｅｒ株式会社, 天野エンザイム株式会社 filed Critical Ｓｐｉｂｅｒ株式会社
Priority to JP2023547165A priority Critical patent/JPWO2023038154A1/ja
Publication of WO2023038154A1 publication Critical patent/WO2023038154A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
    • D06M15/01—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
    • D06M15/15—Proteins or derivatives thereof
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic

Definitions

  • the present invention relates to a large-diameter artificial polypeptide fiber, a method for producing the same, and an adhesive.
  • Patent Document 1 discloses a biodegradable artificial polypeptide fiber that can be industrially produced in desired thickness and length.
  • An artificial polypeptide fiber is produced by, for example, extruding a dope solution in which an artificial protein, which is a type of artificial polypeptide, is dissolved in a predetermined solvent to form a linear molded body, and then extruding the linear molded body in a coagulation bath or in the atmosphere. prepared by removing the solvent from
  • the linear molded product discharged from the spinning nozzle contains a large amount of solvent. It takes time. If the solvent remains in the artificial polypeptide fiber, problems such as the inability to properly form the fiber and the inability to obtain a certain strength occur, resulting in a decrease in the efficiency of fiber production.
  • Patent Document 2 When obtaining thick fibers, a method is often used to obtain seemingly thick bundled fibers by bundling thin raw material fibers and adhering them with a synthetic adhesive (for example, Patent Document 2).
  • a large-diameter pile for flocking is manufactured by covering and hardening a plurality of small-diameter piles with a binder.
  • Nitrile rubber, polyurethane rubber, vinyl chloride resin, acrylic acid ester resin, ethylene-vinyl acetate copolymer resin, phenol resin, or epoxy resin is used for the binder.
  • the presence of the binder that occupies most of the large-diameter pile can impair the flexibility and biodegradability of the entire fiber.
  • the present invention provides the following [1] to [17].
  • [1] A step of bundling a plurality of raw fibers containing an artificial polypeptide; a step of contacting the obtained bundle of raw material fibers with a composition containing a binder and an enzyme;
  • a method of making an engineered polypeptide fiber comprising: [2] The method for producing an artificial polypeptide fiber according to [1], wherein the enzyme contains an oxidase.
  • the oxidase is at least one selected from the group consisting of laccase, bilirubin oxidase, glucose oxidase, and peroxidase.
  • [4] The method for producing an artificial polypeptide fiber according to any one of [1] to [3], wherein the artificial polypeptide contains a structural protein.
  • [5] The method for producing an artificial polypeptide fiber according to any one of [1] to [3], wherein the artificial polypeptide contains fibroin.
  • [6] The method for producing an artificial polypeptide fiber according to any one of [1] to [3], wherein the artificial polypeptide contains spider silk fibroin.
  • [8] An artificial polypeptide fiber, in which a plurality of raw fibers containing an artificial polypeptide are bonded together via a binder.
  • An adhesive for bonding together fibers comprising an artificial polypeptide comprising: An adhesive comprising a binder and an enzyme that reacts with at least one of the artificial polypeptide and the binder.
  • the adhesive of [12], wherein the enzyme is an oxidase.
  • the oxidase is at least one selected from the group consisting of laccase, bilirubin oxidase, glucose oxidase, and peroxidase.
  • the artificial polypeptide comprises a structural protein.
  • the artificial polypeptide contains fibroin.
  • the artificial polypeptide comprises spider silk fibroin.
  • an artificial polypeptide fiber having a new bundle-like structure and a method for producing the same by binding a binder and a raw material fiber through an enzymatic reaction.
  • the resulting artificial polypeptide fiber has a bundle-like structure, each of which is directly or indirectly bound by an enzymatic reaction to form a single fiber with a larger diameter.
  • the fibers produced by the method according to the present invention are bound with a binder after producing small-diameter fibers. It is possible to greatly reduce the resistance and increase the manufacturing efficiency.
  • FIG. 1 is a schematic diagram showing a cross section of an artificial polypeptide fiber according to one embodiment of the present invention
  • FIG. FIG. 2 is a schematic diagram showing an example of a domain sequence of artificial fibroin.
  • FIG. 4 is a diagram showing the distribution of z/w (%) values of naturally occurring fibroin.
  • FIG. 4 is a diagram showing the distribution of x/y (%) values of naturally occurring fibroin.
  • FIG. 2 is a schematic diagram showing an example of a domain sequence of artificial fibroin.
  • 1 is a schematic diagram showing an example of a fibroin domain sequence.
  • FIG. BRIEF DESCRIPTION OF THE DRAWINGS It is explanatory drawing which shows roughly an example of the spinning apparatus for manufacturing a raw material fiber.
  • 1 is a photograph showing an example of a method for producing an artificial polypeptide according to an embodiment of the present invention.
  • a first embodiment of the present invention includes a step of bundling a plurality of raw fibers containing an artificial polypeptide, and a step of contacting the resulting bundle of raw fibers with a composition containing a binder and an enzyme.
  • a method for producing an artificial polypeptide fiber includes a step of bundling a plurality of raw fibers containing an artificial polypeptide, and a step of contacting the resulting bundle of raw fibers with a composition containing a binder and an enzyme.
  • an artificial polypeptide fiber by bundling a plurality of raw fibers containing an artificial polypeptide and bringing them into contact with a composition containing a binder and an enzyme, the enzyme binds to at least one of the artificial polypeptide and the binder.
  • the enzyme By reacting to chemically cross-link at least one of raw material fiber to raw material fiber, raw material fiber to binder, and binder to binder, an artificial polypeptide fiber can be produced.
  • the step of bundling a plurality of raw fibers may be a step of simply gathering the raw fibers into a bundle by hand. It may be a process.
  • the cylindrical container is not particularly limited, and any cylindrical container having a desired inner diameter can be used.
  • the inner diameter of the cylindrical container is preferably a size suitable for the thickness of the target artificial polypeptide fiber, for example, 1.2 to 2 times the size of the target artificial polypeptide fiber. , preferably 1.3 to 1.7 times as large.
  • the number of raw material fibers to be bundled can be appropriately adjusted in the range of, for example, 5 to 100, 10 to 90, 20 to 80, 30 to 70, or 40 to 60.
  • the number of raw material fibers to be bundled is reflected in the fiber diameter of the artificial polypeptide fiber (large-diameter artificial polypeptide fiber), and the larger the number of raw material fibers, the thicker the resulting artificial polypeptide fiber can be.
  • the raw material fiber is a fiber containing an artificial polypeptide, or may be a fiber consisting only of an artificial polypeptide.
  • An engineered polypeptide may include a backbone derived from an engineered protein.
  • Engineered proteins may include engineered structural proteins.
  • Artificial structural proteins may include artificial fibroin.
  • Artificial fibroin may include artificial modified spider silk fibroin.
  • artificial proteins include any proteins that can be produced on an industrial scale, such as proteins that can be used for industrial purposes.
  • the term "applicable for industrial use” means, for example, that it can be used for various general-purpose materials used indoors and outdoors, and various materials used for medical applications, clothing applications, and the like.
  • Specific examples of proteins that can be used industrially include structural proteins.
  • Specific examples of structural proteins include spider silk, silkworm silk, keratin, collagen, elastin, resilin, and proteins derived from these.
  • artificial fibroin is preferable, and artificial spider silk fibroin (artificial modified spider silk fibroin) is more preferable.
  • Artificial proteins include recombinant proteins and synthetic proteins.
  • the term "artificial protein” as used herein means an artificially produced protein.
  • An artificial protein may be a protein whose domain sequence differs from the amino acid sequence of a naturally occurring protein, or may be a protein whose amino acid sequence is identical to that of a naturally occurring protein.
  • the "artificial protein” may be one that uses the amino acid sequence of a naturally-occurring protein as it is, or one in which the amino acid sequence is modified based on the amino acid sequence of a naturally-occurring protein (for example, a cloned naturally-occurring protein).
  • the amino acid sequence may be modified by modifying the gene sequence of the derived protein), or artificially designed and synthesized without relying on naturally occurring proteins (e.g., those that encode the designed amino acid sequence a desired amino acid sequence obtained by chemically synthesizing a nucleic acid).
  • the artificial polypeptide may have 50 or more amino acid residues.
  • the number of amino acid residues is, for example, 100 or more, 150 or more, 200 or more, 250 or more, 300 or more, 350 or more, 400 or more, 450 or more, or 500 or more.
  • the number of amino acid residues is, for example, 5000 or less, 4500 or less, 4000 or less, 3500 or less, 3000 or less, 2500 or less, 2000 or less, 1500 or less, 1000 or less. Solubility in solvents tends to increase as the number of amino acid residues decreases.
  • the artificial polypeptide may have a hydrophilic polypeptide backbone or a hydrophobic polypeptide backbone.
  • the properties of the raw material fiber can be shifted to the hydrophobic side compared to when the artificial polypeptide has a hydrophilic polypeptide backbone. It becomes possible to control the hydrophobicity of the entire fiber over a wider range.
  • the hydrophobicity of the hydrophobic polypeptide backbone can be estimated using the average hydropathic index value described below as an index.
  • the average hydropathic index value of the hydrophobic polypeptide is, for example, 0.00 or more, 0.10 or more, 0.20 or more, 0.22 or more, 0.25 or more, 0.30 or more, 0.35 or more. , 0.40 or greater, 0.45 or greater, 0.50 or greater, 0.55 or greater, 0.60 or greater, 0.65 or greater, or 0.70 or greater.
  • the upper limit is not particularly limited, it may be, for example, 1.00 or less, or 0.7 or less.
  • the hydrophobic polypeptide preferably has low solubility in an aqueous solution of lithium bromide (concentration: 9M) at 60°C.
  • This solubility can be evaluated using a compound (polypeptide) corresponding to the hydrophobic polypeptide backbone or a polypeptide obtained by decomposing a synthetic polymer and isolating only the hydrophobic polypeptide backbone.
  • the maximum concentration when the polypeptide is dissolved in an aqueous lithium bromide solution (concentration: 9 M) at 60° C. is, for example, less than 30% by mass, less than 25% by mass, less than 20% by mass, less than 15% by mass, It may be less than 10 wt%, less than 5 wt%, or less than 1 wt%.
  • the hydrophobic polypeptide backbone may be one that is completely insoluble in a lithium bromide aqueous solution (concentration: 9M) at 60°C.
  • the hydrophobic polypeptide skeleton preferably has a large contact angle with water.
  • the contact angle of water is measured by using a membrane composed of a polypeptide obtained by decomposing a compound (polypeptide) corresponding to the hydrophobic polypeptide skeleton or a synthetic polymer and isolating only the hydrophobic polypeptide skeleton on a substrate. can be formed and evaluated using the film.
  • a polypeptide that forms a film with a contact angle of 55° or more after 5 seconds of water being dropped onto the film is preferred as the hydrophobic polypeptide backbone.
  • the contact angle may be, for example, 60° or greater, 65° or greater, or 70° or greater.
  • the hydrophobic polypeptide backbone is preferably one with excellent hot water resistance. Hydrothermal resistance can be evaluated using a compound (polypeptide) corresponding to the hydrophobic polypeptide backbone or a polypeptide obtained by decomposing a synthetic polymer and isolating only the hydrophobic polypeptide backbone.
  • the polypeptide scaffold according to this embodiment may be, for example, a structural protein.
  • a structural protein means a protein involved in the structure of a living body, a protein constituting a structure produced by a living body, or a protein derived from them.
  • Structural proteins also refer to proteins that self-aggregate under certain conditions to form structures such as fibers, films, resins, gels, micelles, and nanoparticles.
  • a structural protein can be said to be a protein in which a characteristic amino acid sequence or a motif consisting of several amino acid residues is repeatedly present and which forms the skeleton of an organism or material.
  • Structural proteins in nature include, for example, fibroin, keratin, collagen, elastin and resilin.
  • the structural protein may be an artificial structural protein.
  • artificial structural protein means a structural protein that is artificially produced.
  • the artificial structural protein may be a structural protein produced by microorganisms through genetic recombination, and includes those with improved amino acid sequences from the viewpoint of moldability and productivity, and is not limited to the sequence of a naturally occurring structural protein.
  • amino acids with smaller side chains are more likely to form hydrogen bonds, making it easier to obtain a strong molded product.
  • alanine and glycine residues are amino acids with non-polar side chains, they are arranged so as to face inward during the folding process during polypeptide production, and tend to adopt an ⁇ -helical structure or a ⁇ -sheet structure. Therefore, it is desirable that the ratio of amino acids such as glycine residues, alanine residues and serine residues is high.
  • the alanine residue content may be, for example, 10 to 40%, 12 to 40%, 15 to 40%, 18 to 40%, 20 to 40%, or It may be 22-40%.
  • the glycine residue content may be, for example, 10 to 55%, 11 to 55%, 13 to 55%, 15 to 55%, 18 to 55%, 20 to 55%. It may be 55%, 22-55%, or 25-55%.
  • amino acid residue content is a value represented by the following formula.
  • Alanine residue content (number of alanine residues contained in polypeptide/number of total amino acid residues in polypeptide) x 100 (%)
  • the glycine residue content, serine residue content, threonine residue content, proline residue content and tyrosine residue content are defined in the above formulas, in which alanine residues are replaced with glycine residues, serine residues, It is synonymous with what is read as threonine residue, proline residue and tyrosine residue.
  • An artificial structural protein according to one embodiment may have a repeat sequence. That is, the polypeptide according to this embodiment may have a plurality of amino acid sequences (repetitive sequence units) with high sequence identity within the polypeptide.
  • the number of amino acid residues in the repeat sequence unit is preferably 6-200.
  • the sequence identity between repeat sequence units may be, for example, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more.
  • the hydrophobicity (hydropathic index) of the repeating sequence unit is, for example, -0.80 or more, -0.70 or more, -0.60 or more, -0.50 or more, -0.40 or more, - 0.30 or more, -0.20 or more, -0.10 or more, 0.00 or more, 0.22 or more, 0.25 or more, 0.30 or more, 0.35 or more, 0.40 or more, 0.45 0.50 or more, 0.55 or more, 0.60 or more, 0.65 or more, or 0.70 or more.
  • the upper limit of the hydrophobicity of the repeating sequence unit is not particularly limited, it may be, for example, 1.0 or less, or 0.7 or less.
  • An artificial structural protein may comprise an (A) n motif.
  • the (A) n motif means an amino acid sequence mainly composed of alanine residues.
  • the number of amino acid residues in the n motif may be 2-27 and may be an integer from 2-20, 2-16, or 2-12.
  • the ratio of the number of alanine residues to the total number of amino acid residues in the n motif may be 40% or more, 60% or more, 70% or more, 80% or more, 83% or more, 85% or more, It may be 86% or more, 90% or more, 95% or more, or 100% (meaning that it is composed only of alanine residues).
  • Fibroin includes, for example, naturally occurring fibroin.
  • Naturally occurring fibroin includes, for example, fibroin produced by insects or arachnids.
  • fibroin produced by insects include, for example, Bombyx mori, Bombyx mandarina, Antheraea yamamai, Anteraea pernyi, Eriogyna pyretorum, and Pilos cylinthia silkworm. ), silk proteins produced by silkworms such as Samia cynthia, Caligura japonica, Antheraea mylitta, and Antheraea assama, and exhaled by Vespa simillima xantoptera larvae Hornet silk protein.
  • fibroin produced by insects include silkworm fibroin L chain (GenBank Accession No. M76430 (nucleotide sequence), AAA27840.1 (amino acid sequence)).
  • fibroin produced by spiders include, for example, spiders belonging to the genus Araneus such as Araneus spiders, Araneus spiders, Red spiders, Green spiders, and Beetle spiders; Spiders belonging to the genus Pronus, spiders belonging to the genus Pronus such as spiders belonging to the Spiders belonging to the genus Gasteracantha, spiders belonging to the genus Ordgarius such as the genus Ordgarius and the spiders belonging to the genus Ordgarius, spiders belonging to the genus Argiope such as the argiope spider, the argiope spider, and the argiope spider, and the like Spiders belonging to the genus Arachnura, spiders belonging to the genus Acusilas, such as spiders, spiders belonging to the genus Cytophora, such as spiders, spiders, and spiders Spider silk proteins produced by spiders belonging to the genus Cyclosa, such as spiders belonging to the
  • fibroin produced by spiders include fibroin-3 (adf-3) [derived from Araneus diadematus] (GenBank accession number AAC47010 (amino acid sequence), U47855 (nucleotide sequence)), fibroin- 4(adf-4) [derived from Araneus diadematus] (GenBank Accession No. AAC47011 (amino acid sequence), U47856 (nucleotide sequence)), dragline silk protein spidroin 1 [derived from Nephila clavipes] (GenBank Accession No.
  • AAC04504 (amino acid sequence), U37520 (nucleotide sequence)), major angu11ate spidroin 1 [derived from Latrodectus hesperus] (GenBank accession number ABR68856 (amino acid sequence), EF595246 (nucleotide sequence)), dragline silk protein spidroin 2 [derived from Nephila accession number 2Lan4Aclavata] (amino acid sequence), AF441245 (nucleotide sequence)), major ampullate spidroin 1 [from Euprosthenops australis] (GenBank accession number CAJ00428 (amino acid sequence), AJ973155 (nucleotide sequence)), and major ampullate spidroin 2 [Eanprosthenops] Accession number CAM32249.1 (amino acid sequence), AM490169 (nucleotide sequence)), minor amplified silk protein 1 [Nephil
  • fibroin whose sequence information is registered in NCBI GenBank.
  • sequence information registered in NCBI GenBank among the sequences that include INV as a division, spidroin, ampullate, fibroin, "silk and polypeptide", or "silk and protein" are described as keywords in DEFINITION It can be confirmed by extracting the specific product character string from the sequence, CDS, and the specific character string from SOURCE to TISSUE TYPE.
  • artificial fibroin means artificially produced fibroin (artificial fibroin).
  • Artificial fibroin may be fibroin that differs from the amino acid sequence of naturally-occurring fibroin, or fibroin that is identical to the amino acid sequence of naturally-occurring fibroin.
  • the artificial fibroin may be a fibrous protein having a structure similar to that of naturally occurring fibroin, or may be fibroin having a sequence similar to the repeating sequence of naturally occurring fibroin.
  • the “sequence similar to the repeat sequence possessed by fibroin” may be a sequence actually possessed by naturally occurring fibroin, or may be a sequence similar thereto.
  • “Artificial fibroin” refers to those obtained by modifying the amino acid sequence of naturally-occurring fibroin (e.g., modifying the gene sequence of cloned naturally-occurring fibroin), as long as it has the amino acid sequence specified in the present disclosure.
  • the amino acid sequence may be modified by the method), or the amino acid sequence may be artificially designed without relying on naturally occurring fibroin (for example, by chemically synthesizing a nucleic acid encoding the designed amino acid sequence). having a desired amino acid sequence).
  • An artificial fibroin with a modified amino acid sequence is also included in the artificial fibroin as long as the amino acid sequence differs from the amino acid sequence of the naturally-derived fibroin.
  • artificial fibroin examples include artificial silk fibroin (modified amino acid sequence of silk protein produced by silkworms), and artificial spider silk fibroin (modified amino acid sequence of spider silk protein produced by spiders). ) and the like.
  • spider silk fibroin is relatively easy to fibrillate and has high fiber-forming ability, so the artificial fibroin preferably contains artificial spider silk fibroin, more preferably Consists of artificial spider silk fibroin.
  • an artificial fibroin (first artificial fibroin) derived from a dragline silk protein produced in the major pituitary gland of spiders, a glycine residue content of artificial fibroin with reduced domain sequence (second artificial fibroin), (A) artificial fibroin with domain sequence with reduced n- motif content (third artificial fibroin), content of glycine residues, and (A) an artificial fibroin with a reduced n- motif content (fourth artificial fibroin), an artificial fibroin having a domain sequence containing a region with a locally large hydrophobicity index (fifth artificial fibroin), and glutamine Artificial fibroins with domain sequences with reduced content of residues (sixth artificial fibroin) are included.
  • a first artificial fibroin includes a protein comprising a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the number of amino acid residues in the (A) n motif is preferably an integer of 3 to 20, more preferably an integer of 4 to 20, still more preferably an integer of 8 to 20, and an integer of 10 to 20. is even more preferred, integers from 4 to 16 are even more preferred, integers from 8 to 16 are particularly preferred, and integers from 10 to 16 are most preferred.
  • the number of amino acid residues constituting REP in Formula 1 is preferably 10 to 200 residues, more preferably 10 to 150 residues, and 20 to 100 residues. and even more preferably 20 to 75 residues.
  • the total number of glycine residues, serine residues and alanine residues contained in the amino acid sequence represented by Formula 1: [(A) n motif-REP] m is amino acid residue It is preferably 40% or more, more preferably 60% or more, and even more preferably 70% or more of the total number.
  • the first artificial fibroin comprises an amino acid sequence unit represented by Formula 1: [(A) n motif-REP] m and has an amino acid sequence whose C-terminal sequence is shown in any one of SEQ ID NOS: 1 to 3, or
  • the polypeptide may be an amino acid sequence having 90% or more homology with the amino acid sequence shown in any one of SEQ ID NOs: 1-3.
  • amino acid sequence shown in SEQ ID NO: 1 is identical to the amino acid sequence consisting of the C-terminal 50 amino acids of the amino acid sequence of ADF3 (GI: 1263287, NCBI), and the amino acid sequence shown in SEQ ID NO: 2 has the sequence It is identical to the amino acid sequence shown in No. 1 with 20 residues removed from the C-terminus, and the amino acid sequence shown in SEQ ID No. 3 has 29 residues removed from the C-terminus of the amino acid sequence shown in SEQ ID No. 1. Identical to the amino acid sequence.
  • the amino acid sequence represented by SEQ ID NO: 4 (recombinant spider silk protein ADF3 KaiLargeNRSH1), or (1-ii) the amino acid sequence represented by SEQ ID NO: 4 and 90
  • Artificial fibroin comprising amino acid sequences having greater than % sequence identity
  • the sequence identity is 95% or greater.
  • the amino acid sequence shown by SEQ ID NO: 4 is the amino acid sequence (SEQ ID NO: 5) consisting of an initiation codon, a His10 tag, and an HRV3C protease (Human rhinovirus 3C protease) recognition site added to the N-terminus of ADF3.
  • the 13th repeat region was increased to approximately double and mutated so that translation stops at the 1154th amino acid residue.
  • the C-terminal amino acid sequence of the amino acid sequence shown by SEQ ID NO:4 is identical to the amino acid sequence shown by SEQ ID NO:3.
  • the (1-i) artificial fibroin may consist of the amino acid sequence shown in SEQ ID NO:4.
  • the second artificial fibroin has an amino acid sequence in which the domain sequence has a reduced content of glycine residues compared to the naturally-derived fibroin.
  • the second artificial fibroin can be said to have an amino acid sequence corresponding to at least one or more glycine residues in REP being replaced with another amino acid residue, as compared with the naturally occurring fibroin. .
  • the second artificial fibroin has a domain sequence of GGX and GPGXX (where G is a glycine residue, P is a proline residue, and X is an amino acid residue other than glycine) in REP compared to the naturally-derived fibroin.
  • G is a glycine residue
  • P is a proline residue
  • X is an amino acid residue other than glycine
  • it has an amino acid sequence corresponding to at least one or more glycine residues in the motif sequence being replaced with another amino acid residue
  • the percentage of the motif sequence in which the above-mentioned glycine residue is replaced with another amino acid residue may be 10% or more of the entire motif sequence.
  • the second artificial fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m , and from the domain sequence to the (A) n motif located on the most C-terminal side to the domain sequence
  • w is the total number of amino acid residues in the sequence excluding the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence
  • z/w is 30% or more, It may have an amino acid sequence that is 40% or more, 50% or more, or 50.9% or more.
  • the number of alanine residues relative to the total number of amino acid residues in the n motif may be 83% or more, preferably 86% or more, more preferably 90% or more, and 95% or more. 100% (meaning composed only of alanine residues) is even more preferred.
  • the second artificial fibroin preferably has an increased content of the amino acid sequence consisting of XGX by substituting one glycine residue in the GGX motif with another amino acid residue. 6.
  • the content of the amino acid sequence consisting of GGX in the domain sequence is preferably 30% or less, more preferably 20% or less, even more preferably 10% or less. % or less, even more preferably 4% or less, and particularly preferably 2% or less.
  • the content ratio of the amino acid sequence consisting of GGX in the domain sequence can be calculated by the same method as the method for calculating the content ratio (z/w) of the amino acid sequence consisting of XGX below.
  • a method for calculating z/w will be described in more detail.
  • a fibroin artificial fibroin or naturally occurring fibroin
  • a domain sequence represented by Formula 1: [(A) n motif-REP] m the (A) n located on the most C-terminal side from the domain sequence
  • An amino acid sequence consisting of XGX is extracted from all REPs contained in the sequence excluding the sequence from the motif to the C-terminus of the domain sequence.
  • z/w is preferably 50.9% or more, more preferably 56.1% or more, even more preferably 58.7% or more, and 70% or more. and even more preferably 80% or more.
  • the upper limit of z/w is not particularly limited, it may be, for example, 95% or less.
  • the second artificial fibroin can be obtained, for example, by substituting at least part of the nucleotide sequence encoding the glycine residue from the cloned naturally-derived fibroin gene sequence so as to encode another amino acid residue. Obtainable. At this time, one glycine residue in the GGX motif and the GPGXX motif may be selected as the glycine residue to be modified, or may be substituted so that z/w is 50.9% or more. Alternatively, for example, it can be obtained by designing an amino acid sequence that satisfies the above aspect from the amino acid sequence of naturally occurring fibroin, and chemically synthesizing a nucleic acid encoding the designed amino acid sequence.
  • one or more amino acid residues are further substituted or deleted. , insertions and/or additions may be made to the amino acid sequence.
  • the other amino acid residue mentioned above is not particularly limited as long as it is an amino acid residue other than glycine residue, but valine (V) residue, leucine (L) residue, isoleucine (I) residue, methionine ( Hydrophobic amino acid residues such as M) residues, proline (P) residues, phenylalanine (F) residues and tryptophan (W) residues, glutamine (Q) residues, asparagine (N) residues, serine (S ) residues, lysine (K) residues and glutamic acid (E) residues are preferred, and hydrophilic amino acid residues such as valine (V) residues, leucine (L) residues, isoleucine (I) residues, phenylalanine ( F) residues and glutamine (Q) residues are more preferred, and glutamine (Q) residues are even more preferred.
  • the second artificial fibroin examples include (2-i) SEQ ID NO: 6 (Met-PRT380), SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525) or SEQ ID NO: 9 (Met -PRT799), or (2-ii) SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. Mention may be made of artificial fibroin.
  • the artificial fibroin of (2-i) will be explained.
  • the amino acid sequence shown by SEQ ID NO: 6 is obtained by replacing all GGX in REP of the amino acid sequence shown by SEQ ID NO: 10 (Met-PRT313) corresponding to naturally occurring fibroin with GQX.
  • the amino acid sequence shown by SEQ ID NO: 7 is obtained by deleting every two (A) n motifs from the amino acid sequence shown by SEQ ID NO: 6 from the N-terminal side to the C-terminal side, and furthermore, in front of the C-terminal sequence. [(A) n motif-REP] is inserted into the .
  • the amino acid sequence shown in SEQ ID NO: 8 has two alanine residues inserted on the C-terminal side of each (A) n motif of the amino acid sequence shown in SEQ ID NO: 7, and a partial glutamine (Q) residue. It is obtained by substituting serine (S) residues and deleting some amino acids on the C-terminal side so that the molecular weight is almost the same as that of SEQ ID NO:7.
  • the amino acid sequence shown by SEQ ID NO: 9 is a region of 20 domain sequences present in the amino acid sequence shown by SEQ ID NO: 7 (however, several amino acid residues on the C-terminal side of the region are substituted). A predetermined hinge sequence and a His tag sequence are added to the C-terminus of a sequence in which is repeated four times.
  • the z/w value in the amino acid sequence represented by SEQ ID NO: 10 (corresponding to naturally occurring fibroin) is 46.8%.
  • the z/w values in the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, the amino acid sequence represented by SEQ ID NO: 8, and the amino acid sequence represented by SEQ ID NO: 9 are each 58.7%, 70.1%, 66.1% and 70.0%.
  • the value of x/y in the jagged ratio (described later) of 1:1.8 to 11.3 of the amino acid sequences shown in SEQ ID NO: 10, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9 is 15.0%, 15.0%, 93.4%, 92.7% and 89.8% respectively.
  • the (2-i) artificial fibroin may consist of the amino acid sequence shown in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.
  • the artificial fibroin (2-ii) contains an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.
  • the artificial fibroin of (2-ii) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • (2-ii) artificial fibroin has 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, and XGX contained in REP ( where X represents an amino acid residue other than glycine). is preferably 50.9% or more.
  • the second artificial fibroin may contain a tag sequence at either or both of the N-terminus and C-terminus. This makes it possible to isolate, immobilize, detect and visualize artificial fibroin.
  • tag sequences include affinity tags that utilize specific affinity (binding, affinity) with other molecules.
  • affinity tag is a histidine tag (His tag).
  • His tag is a short peptide in which about 4 to 10 histidine residues are lined up, and because it has the property of specifically binding to metal ions such as nickel, artificial fibroin is isolated by metal chelating chromatography.
  • SEQ ID NO: 11 an amino acid sequence containing a His tag sequence and a hinge sequence.
  • tag sequences such as glutathione-S-transferase (GST) that specifically binds to glutathione and maltose binding protein (MBP) that specifically binds to maltose can be used.
  • GST glutathione-S-transferase
  • MBP maltose binding protein
  • epitope tags that utilize antigen-antibody reactions. By adding an antigenic peptide (epitope) as a tag sequence, an antibody against the epitope can be bound.
  • epitope tags include HA (peptide sequence of influenza virus hemagglutinin) tag, myc tag, FLAG tag, and the like. Artificial fibroin can be easily purified with high specificity by using an epitope tag.
  • a tag sequence that can be cleaved by a specific protease can also be used.
  • Artificial fibroin from which the tag sequence has been cut off can also be recovered by treating the protein adsorbed via the tag sequence with protease.
  • artificial fibroin containing a tag sequence (2-iii) the amino acid represented by SEQ ID NO: 12 (PRT380), SEQ ID NO: 13 (PRT410), SEQ ID NO: 14 (PRT525) or SEQ ID NO: 15 (PRT799) or (2-iv) an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15. .
  • amino acid sequences shown in SEQ ID NO: 16 are SEQ ID NO: 10, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.
  • amino acid sequence shown in SEQ ID NO: 11 was added to the N-terminus of the amino acid sequence shown.
  • the (2-iii) artificial fibroin may consist of the amino acid sequence shown in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15.
  • the (2-iv) artificial fibroin contains an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15.
  • the artificial fibroin of (2-iv) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • (2-iv) artificial fibroin has 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15, and is contained in REP ( where X represents an amino acid residue other than glycine). is preferably 50.9% or more.
  • the second artificial fibroin may contain a secretion signal for releasing the protein produced in the artificial protein production system to the outside of the host.
  • the sequence of the secretory signal can be appropriately set according to the type of host.
  • a third artificial fibroin has an amino acid sequence in which the domain sequence has a reduced content of (A) n motifs compared to the naturally-occurring fibroin.
  • the domain sequence of the third artificial fibroin can be said to have an amino acid sequence corresponding to deletion of at least one or a plurality of (A) n motifs compared to the naturally-occurring fibroin.
  • the third artificial fibroin may have an amino acid sequence corresponding to 10-40% deletion of the (A) n motif from the naturally-occurring fibroin.
  • the third artificial fibroin has a domain sequence at least one (A) n motif for every 1-3 (A) n motifs from the N-terminal side to the C-terminal side compared to the naturally occurring fibroin. may have an amino acid sequence corresponding to the deletion of
  • the third artificial fibroin has at least two consecutive (A) n motif deletions from the N-terminal side to the C-terminal side and one (A ) may have an amino acid sequence corresponding to deletion of n motifs repeated in this order.
  • the third artificial fibroin may have an amino acid sequence corresponding to deletion of at least every two (A) n motifs from the N-terminal side to the C-terminal side of the domain sequence. .
  • the third artificial fibroin comprises a domain sequence represented by the formula 1: [(A) n motif-REP] m , with two adjacent [(A) n motifs from the N-terminal side to the C-terminal side.
  • -REP] unit sequentially compares the number of amino acid residues of REP, and when the number of amino acid residues of REP with a small number of amino acid residues is set to 1, the ratio of the number of amino acid residues of the other REP is 1.8 to 11.
  • the total number of amino acid residues of the domain sequence is y Furthermore, it may have an amino acid sequence in which x/y is 20% or more, 30% or more, 40% or more, or 50% or more.
  • the number of alanine residues relative to the total number of amino acid residues in the n motif may be 83% or more, preferably 86% or more, more preferably 90% or more, and 95% or more. 100% (meaning composed only of alanine residues) is even more preferred.
  • FIG. 2 shows the domain sequence of the artificial fibroin with the N-terminal and C-terminal sequences removed.
  • the domain sequence is, from the N-terminal side (left side), (A) n motif-first REP (50 amino acid residues)-(A) n motif-second REP (100 amino acid residues)-(A) n Motif-third REP (10 amino acid residues)-(A) n motif-fourth REP (20 amino acid residues)-(A) n motif-fifth REP (30 amino acid residues)-(A) It has a sequence called n motif.
  • a set of [(A) n motif-REP] units having a ratio of 1.8 to 11.3 for the number of amino acid residues of the other is set to 1 for the one with the smaller number of amino acid residues. It is indicated by a solid line. This ratio is referred to herein as the serration ratio.
  • a set of [(A) n motif-REP] units in which the other amino acid residue number ratio is less than 1.8 or greater than 11.3 when the number of amino acid residues is less than 1 is indicated by a dashed line. Indicated.
  • each pattern the numbers of all amino acid residues of two adjacent [(A) n motif-REP] units indicated by solid lines are summed up (not only REP but also the number of amino acid residues of (A) n motifs). be.). Then, the added total values are compared, and the total value (maximum total value) of the pattern with the maximum total value is defined as x. In the example shown in FIG. 2, the total value of pattern 1 is the largest.
  • x/y (%) can be calculated by dividing x by the total number of amino acid residues y in the domain sequence.
  • x/y is preferably 50% or more, more preferably 60% or more, even more preferably 65% or more, and even more preferably 70% or more. Preferably, 75% or more is even more preferable, and 80% or more is particularly preferable.
  • the upper limit of x/y is not particularly limited, and may be, for example, 100% or less.
  • x/y is preferably 89.6% or more, and when the serration ratio is 1:1.8 to 3.4, x /y is preferably 77.1% or more, and when the serration ratio is 1:1.9 to 8.4, x/y is preferably 75.9% or more, and the serration ratio is 1 : 1.9 to 4.1, x/y is preferably 64.2% or more.
  • x/y is 46.4% or more. is preferably 50% or more, more preferably 55% or more, even more preferably 60% or more, even more preferably 70% or more, and 80% or more It is particularly preferred to have The upper limit of x/y is not particularly limited as long as it is 100% or less.
  • fibroin whose amino acid sequence information is registered in NCBI GenBank was confirmed by the method exemplified, and 663 types of fibroin (among them, 415 types of arachnid-derived fibroin) were extracted. Of all the extracted fibroin, from the amino acid sequence of naturally occurring fibroin composed of the domain sequence represented by the formula 1: [(A) n motif-REP] m , x/y was calculated.
  • FIG. 4 shows the results when the serration ratio is 1:1.9 to 4.1.
  • the horizontal axis in FIG. 4 indicates x/y (%), and the vertical axis indicates frequency.
  • the x/y ratios for naturally occurring fibroin are all less than 64.2% (64.14% being the highest).
  • one or more sequences encoding (A) n motifs are deleted from the cloned natural fibroin gene sequence such that x/y is 64.2% or more.
  • an amino acid sequence corresponding to deletion of one or more (A) n motifs is designed such that x/y is 64.2% or more from the amino acid sequence of naturally occurring fibroin. It can also be obtained by chemically synthesizing a nucleic acid encoding the amino acid sequence described above.
  • one or more amino acid residues are substituted, deleted, inserted and/or added. Alterations in the amino acid sequence corresponding to what has been done may be made.
  • third artificial fibroin examples include (3-i) SEQ ID NO: 17 (Met-PRT399), SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525) or SEQ ID NO: 9 (Met -PRT799), or (3-ii) SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. Mention may be made of artificial fibroin.
  • the artificial fibroin of (3-i) will be explained.
  • the amino acid sequence represented by SEQ ID NO: 17 is every two (A) n
  • the motif was deleted and one [(A) n motif-REP] was inserted in front of the C-terminal sequence.
  • the amino acid sequence shown by SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9 is as described for the second artificial fibroin.
  • the value of x/y at the jagged ratio of 1:1.8 to 11.3 of the amino acid sequence represented by SEQ ID NO: 10 is 15.0%.
  • the x/y values of the amino acid sequence shown by SEQ ID NO: 17 and the amino acid sequence shown by SEQ ID NO: 7 are both 93.4%.
  • the value of x/y in the amino acid sequence shown by SEQ ID NO: 8 is 92.7%.
  • the value of x/y in the amino acid sequence shown by SEQ ID NO: 9 is 89.8%.
  • the z/w values in the amino acid sequences represented by SEQ ID NO: 10, SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9 are 46.8%, 56.2%, 70.1%, 66.0%, respectively. 1% and 70.0%.
  • the (3-i) artificial fibroin may consist of the amino acid sequence shown in SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.
  • the artificial fibroin (3-ii) contains an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.
  • the artificial fibroin of (3-ii) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • the artificial fibroin of (3-ii) has a sequence identity of 90% or more with the amino acid sequence shown in SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, and from the N-terminal side to the C-terminal side , the numbers of amino acid residues of REP of two adjacent [(A) n motif-REP] units are sequentially compared, and when the number of amino acid residues of REP with a small number of amino acid residues is set to 1, the number of amino acid residues of the other Amino acid residues of two adjacent [(A) n motif-REP] units with a ratio of the number of amino acid residues of REP of 1.8 to 11.3 (Giza ratio is 1:1.8 to 11.3) It is preferable that x/y is 64.2% or more, where x is the maximum sum of the cardinal numbers and y is the total number of amino acid residues in the domain sequence.
  • the third artificial fibroin may contain the tag sequence described above at either or both of the N-terminus and C-terminus.
  • artificial fibroin containing a tag sequence (3-iii) the amino acid represented by SEQ ID NO: 18 (PRT399), SEQ ID NO: 13 (PRT410), SEQ ID NO: 14 (PRT525) or SEQ ID NO: 15 (PRT799) sequence, or (3-iv) an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15. .
  • amino acid sequences represented by SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15 have SEQ ID NO: 11 at the N-terminus of the amino acid sequences represented by SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.
  • the amino acid sequence shown in (including His tag sequence and hinge sequence) is added.
  • the artificial fibroin of (3-iii) may consist of the amino acid sequence shown in SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15.
  • the (3-iv) artificial fibroin contains an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15.
  • the artificial fibroin of (3-iv) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • (3-iv) artificial fibroin has 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15, and , the numbers of amino acid residues of REP of two adjacent [(A) n motif-REP] units are sequentially compared, and when the number of amino acid residues of REP with a small number of amino acid residues is set to 1, the number of amino acid residues of the other Let x be the maximum value of the total sum of the amino acid residue numbers of two adjacent [(A) n motif-REP] units with a ratio of the number of amino acid residues of REP of 1.8 to 11.3. , x/y is preferably 64.2% or more, where y is the total number of amino acid residues in the domain sequence.
  • the third artificial fibroin may contain a secretion signal for releasing the protein produced in the artificial protein production system to the outside of the host.
  • the sequence of the secretory signal can be appropriately set according to the type of host.
  • the fourth artificial fibroin has an amino acid sequence whose domain sequence has a reduced content of (A) n motifs and a reduced content of glycine residues compared to naturally occurring fibroin. have.
  • the domain sequence of the fourth artificial fibroin has at least one or more (A) n motifs deleted, and at least one or more glycine residues in REP is deleted compared to the naturally-derived fibroin. It can be said to have an amino acid sequence corresponding to substitution with another amino acid residue. That is, the fourth artificial fibroin is an artificial fibroin having both the features of the second artificial fibroin and the third artificial fibroin. Specific aspects and the like are as described in the second artificial fibroin and the third artificial fibroin.
  • the fourth artificial fibroin (4-i) SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525), SEQ ID NO: 9 (Met-PRT799), SEQ ID NO: 13 (PRT410 ), the amino acid sequence shown in SEQ ID NO: 14 (PRT525) or SEQ ID NO: 15 (PRT799), or (4-ii) SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15
  • An artificial fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in .
  • Specific embodiments of the artificial fibroin comprising the amino acid sequence shown in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 are as described above.
  • the fifth artificial fibroin has a domain sequence in which one or more amino acid residues in REP are replaced with amino acid residues with a larger hydrophobicity index than in naturally occurring fibroin, and/or REP It may have an amino acid sequence that includes regions of high local hydrophobicity index corresponding to the insertion of one or more amino acid residues with high hydrophobicity index therein.
  • a region with a locally high hydrophobicity index is preferably composed of 2 to 4 consecutive amino acid residues.
  • the amino acid residue having a large hydrophobicity index is an amino acid selected from isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) and alanine (A).
  • a residue is more preferred.
  • the fifth artificial fibroin has one or more amino acid residues in REP substituted with amino acid residues having a larger hydrophobicity index than the naturally occurring fibroin, and/or one or more
  • amino acid residues having a larger hydrophobicity index than the naturally occurring fibroin and/or one or more
  • one or more amino acid residues are substituted, deleted, inserted and / or added as compared to naturally occurring fibroin
  • one or more hydrophilic amino acid residues eg, amino acid residues with a negative hydrophobicity index
  • hydrophobic amino acid residues from the cloned natural fibroin gene sequence by substituting a group (for example, an amino acid residue with a positive hydrophobicity index) and/or by inserting one or more hydrophobic amino acid residues into REP.
  • substitution of one or more hydrophilic amino acid residues in REP with hydrophobic amino acid residues from the amino acid sequence of naturally occurring fibroin, and/or one or more hydrophobic amino acid residues in REP can also be obtained by designing an amino acid sequence corresponding to the insertion of and chemically synthesizing a nucleic acid encoding the designed amino acid sequence.
  • substitution of one or more hydrophilic amino acid residues in REP with hydrophobic amino acid residues from the amino acid sequence of naturally occurring fibroin, and/or one or more hydrophobic amino acids in REP may also be made.
  • the fifth artificial fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m , and from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence
  • p be the total number of amino acid residues contained in a region where the average value of the hydrophobic index of four consecutive amino acid residues is 2.6 or more in all REPs contained in the sequences excluding the sequences from the domain sequence
  • p/q is 6, where q is the total number of amino acid residues contained in the sequence obtained by excluding the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence from the domain sequence. It may have an amino acid sequence that is greater than or equal to .2%.
  • hydrophobicity index of amino acid residues a known index (Hydropathy index: Kyte J, & Doolittle R (1982) "A simple method for displaying the hydropathic character of a protein", J. Mol. Biol., 157, pp. 105-132).
  • HI hydropathic index
  • sequence A [(A) n motif-REP] m excluding the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence (hereinafter referred to as “sequence A”) is used.
  • sequence A the sequence from the domain sequence represented by the formula 1: [(A) n motif-REP] m excluding the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence.
  • the average value of the hydrophobicity index is obtained for all four consecutive amino acid residues (each amino acid residue is used to calculate the average value 1 to 4 times).
  • a region in which the average value of the hydrophobic index of 4 consecutive amino acid residues is 2.6 or more is specified. Even if a certain amino acid residue corresponds to multiple "4 consecutive amino acid residues with an average hydrophobicity index of 2.6 or more", it is included as one amino acid residue in the region. become.
  • the total number of amino acid residues contained in the region is p. Also, the total number of amino acid residues contained in sequence A is q.
  • p/q is preferably 6.2% or more, more preferably 7% or more, even more preferably 10% or more, and 20% or more. Even more preferably, it is still more preferably 30% or more.
  • the upper limit of p/q is not particularly limited, it may be, for example, 45% or less.
  • the fifth artificial fibroin is, for example, the amino acid sequence of the cloned naturally-occurring fibroin so as to satisfy the above p/q conditions, and one or more hydrophilic amino acid residues in REP (for example, a hydrophobicity index).
  • negative amino acid residue with a hydrophobic amino acid residue (e.g., an amino acid residue with a positive hydrophobicity index), and/or inserting one or more hydrophobic amino acid residues in REP can be obtained by locally modifying an amino acid sequence containing a region with a large hydrophobicity index.
  • one or more amino acid residues in REP have been replaced with amino acid residues having a higher hydrophobicity index compared to naturally-occurring fibroin, and/or one or more
  • further modification corresponding to the substitution, deletion, insertion and/or addition of one or more amino acid residues may be performed. .
  • Amino acid residues with a large hydrophobicity index are not particularly limited, but areoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) and alanine (A). ) are preferred, and valine (V), leucine (L) and isoleucine (I) are more preferred.
  • the fifth artificial fibroin (5-i) an amino acid sequence represented by SEQ ID NO: 19 (Met-PRT720), SEQ ID NO: 20 (Met-PRT665), or SEQ ID NO: 21 (Met-PRT666); or (5-ii) artificial fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21.
  • the amino acid sequence shown by SEQ ID NO: 19 consists of 3 amino acid residues every other REP except for the terminal domain sequence on the C-terminal side with respect to the amino acid sequence shown by SEQ ID NO: 7 (Met-PRT410).
  • the amino acid sequence (VLI) was inserted at two sites, some glutamine (Q) residues were substituted with serine (S) residues, and some amino acids on the C-terminal side were deleted.
  • the amino acid sequence represented by SEQ ID NO: 20 is the amino acid sequence represented by SEQ ID NO: 8 (Met-PRT525) in which an amino acid sequence (VLI) consisting of three amino acid residues is inserted at every other REP. be.
  • the amino acid sequence shown by SEQ ID NO: 21 is obtained by inserting two amino acid sequences (VLI) each consisting of 3 amino acid residues every other REP into the amino acid sequence shown by SEQ ID NO: 8.
  • the (5-i) artificial fibroin may consist of the amino acid sequence shown in SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21.
  • the artificial fibroin (5-ii) contains an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21.
  • the artificial fibroin of (5-ii) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • the artificial fibroin of (5-ii) has 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21, and is located on the most C-terminal side (A) n Amino acids contained in a region where the average hydrophobicity index of 4 consecutive amino acid residues is 2.6 or more in all REPs contained in the domain sequence excluding the sequence from the motif to the C-terminus of the domain sequence Let p be the total number of residues, and q be the total number of amino acid residues contained in the sequence obtained by excluding the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence from the domain sequence. , p/q is preferably 6.2% or more.
  • the fifth artificial fibroin may contain a tag sequence at either or both of the N-terminus and C-terminus.
  • artificial fibroin containing a tag sequence examples include (5-iii) the amino acid sequence represented by SEQ ID NO: 22 (PRT720), SEQ ID NO: 23 (PRT665) or SEQ ID NO: 24 (PRT666), or (5-iv ) Artificial fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO:22, SEQ ID NO:23 or SEQ ID NO:24.
  • amino acid sequences shown in SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24 are added to the N-terminals of the amino acid sequences shown in SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21, respectively, where the amino acid sequence shown in SEQ ID NO: 11 (His tag sequence and hinge sequence) are added.
  • the artificial fibroin of (5-iii) may consist of the amino acid sequence shown in SEQ ID NO:22, SEQ ID NO:23 or SEQ ID NO:24.
  • the (5-iv) artificial fibroin contains an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO:22, SEQ ID NO:23 or SEQ ID NO:24.
  • the artificial fibroin of (5-iv) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • artificial fibroin has 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 22, SEQ ID NO: 23 or SEQ ID NO: 24, and is located on the most C-terminal side (A) n Amino acids contained in a region where the average hydrophobicity index of 4 consecutive amino acid residues is 2.6 or more in all REPs contained in the domain sequence excluding the sequence from the motif to the C-terminus of the domain sequence
  • q be the total number of amino acid residues contained in the sequence obtained by excluding the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence from the domain sequence.
  • p/q is preferably 6.2% or more.
  • the fifth artificial fibroin may contain a secretion signal for releasing the protein produced in the artificial protein production system to the outside of the host.
  • the sequence of the secretory signal can be appropriately set according to the type of host.
  • a sixth artificial fibroin has an amino acid sequence with a reduced content of glutamine residues compared to naturally occurring fibroin.
  • the sixth artificial fibroin preferably contains at least one motif selected from the GGX motif and the GPGXX motif in the REP amino acid sequence.
  • the GPGXX motif content is usually 1% or more, may be 5% or more, and preferably 10% or more.
  • the upper limit of the GPGXX motif content is not particularly limited, and may be 50% or less, or 30% or less.
  • GPGXX motif content is a value calculated by the following method.
  • Formula 1 [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m -(A) n motif fibroin (artificial fibroin or naturally occurring fibroin), the number of GPGXX motifs contained in the region in all REPs contained in the sequence excluding the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence from the domain sequence The number obtained by multiplying the total by three (that is, the total number of G and P in the GPGXX motif) is defined as s, and the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence is taken from the domain sequence.
  • the GPGXX motif content rate is calculated as s/t, where t is the total number of amino acid residues in all REPs excluding (A) n motifs.
  • the "sequence obtained by removing the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence from the domain sequence” is "the most C-terminal side (A)
  • the sequence from the n motif to the C-terminus of the domain sequence” may include sequences that are poorly correlated with sequences characteristic of fibroin, and m is small If the domain sequence is short (that is, if the domain sequence is short), it affects the calculation result of the GPGXX motif content rate, so this effect is to be eliminated.
  • a "GPGXX motif” is located at the C-terminus of REP, it is treated as a "GPGXX motif” even if "XX" is, for example, "AA”.
  • FIG. 2 is a schematic diagram showing the domain sequence of artificial fibroin.
  • the sixth artificial fibroin preferably has a glutamine residue content of 9% or less, more preferably 7% or less, even more preferably 4% or less, and particularly preferably 0%. .
  • glucose residue content is a value calculated by the following method.
  • Formula 1 [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m -(A) n motif fibroin (artificial fibroin or naturally occurring fibroin), all contained in the sequence obtained by excluding the sequence from the (A) n motif located on the most C-terminal side to the C-terminal of the domain sequence from the domain sequence (sequence corresponding to "region A" in FIG.
  • the total number of glutamine residues contained in the region is u
  • the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence is removed from the domain sequence
  • (A) n The glutamine residue content is calculated as u/t, where t is the total number of amino acid residues in all REPs excluding motifs.
  • the target is the "sequence obtained by removing the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence from the domain sequence" because of the reasons described above. It is the same.
  • the sixth artificial fibroin has a domain sequence corresponding to deletion of one or more glutamine residues in REP or substitution with other amino acid residues as compared to the naturally-occurring fibroin. It may have an amino acid sequence.
  • “Another amino acid residue” may be an amino acid residue other than a glutamine residue, but preferably an amino acid residue with a higher hydrophobicity index than a glutamine residue. Hydrophobicity indexes of amino acid residues are shown in Table 1.
  • amino acid residues having a higher hydrophobicity index than glutamine residues include isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M ) amino acid residues selected from alanine (A), glycine (G), threonine (T), serine (S), tryptophan (W), tyrosine (Y), proline (P) and histidine (H); can.
  • amino acid residues selected from isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) and alanine (A) are more preferred.
  • the sixth artificial fibroin has a REP hydrophobicity (hydropathy index) of, for example, -0.80 or more, -0.70, -0.60 or more, -0.50 or more, or -0.40 or more. , -0.30 or more, -0.20 or more, -0.10 or more, 0.00 or more, 0.10 or more, 0.20 or more, 0.22 or more, 0.25 or more, 0.30 or more, 0 .35 or greater, 0.40 or greater, 0.45 or greater, 0.50 or greater, 0.55 or greater, 0.60 or greater, 0.65 or greater, or 0.70 or greater.
  • hydrophobicity of REP There is no particular upper limit to the hydrophobicity of REP, and it may be 1.0 or less, or 0.7 or less.
  • REP hydrophobicity as used herein is a value calculated by the following method.
  • Formula 1 [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m -(A) n motif fibroin (artificial fibroin or naturally occurring fibroin), all contained in the sequence obtained by excluding the sequence from the (A) n motif located on the most C-terminal side to the C-terminal of the domain sequence from the domain sequence (sequence corresponding to "region A" in FIG.
  • the sum of the hydrophobicity indices of each amino acid residue in the region is v, and the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence is removed from the domain sequence, and further ( A) The hydrophobicity of REP is calculated as v/t, where t is the total number of amino acid residues in all REPs excluding n motifs.
  • the reason for targeting is the reason described above. It is the same.
  • a sixth artificial fibroin has a domain sequence lacking one or more glutamine residues in REP and/or one or more glutamine residues in REP compared to the naturally-occurring fibroin
  • the modification corresponding to the substitution of another amino acid residue there may be modifications of the amino acid sequence corresponding to the substitution, deletion, insertion and / or addition of one or more amino acid residues.
  • the sixth artificial fibroin is produced, for example, by deleting one or more glutamine residues in REP from the cloned naturally occurring fibroin gene sequence, and/or by deleting one or more glutamine residues in REP.
  • deletion of one or more glutamine residues in REP from the amino acid sequence of naturally occurring fibroin, and/or substitution of one or more glutamine residues in REP with other amino acid residues It can also be obtained by designing an amino acid sequence corresponding to , and chemically synthesizing a nucleic acid encoding the designed amino acid sequence.
  • sixth artificial fibroin examples include (6-i) SEQ ID NO: 25 (Met-PRT888), SEQ ID NO: 26 (Met-PRT965), SEQ ID NO: 27 (Met-PRT889), SEQ ID NO: 28 (Met -PRT916), SEQ ID NO: 29 (Met-PRT918), SEQ ID NO: 30 (Met-PRT699), SEQ ID NO: 31 (Met-PRT698), SEQ ID NO: 32 (Met-PRT966), SEQ ID NO: 41 (Met-PRT917) or sequence artificial fibroin comprising the amino acid sequence represented by number 42 (Met-PRT1028), or (6-ii) SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 41 or SEQ ID NO: 42, and an artificial fibroin comprising an amino acid sequence having 90% or more sequence identity.
  • the artificial fibroin in (6-i) will be explained.
  • the amino acid sequence shown by SEQ ID NO:25 is obtained by replacing all QQs in the amino acid sequence shown by SEQ ID NO:7 (Met-PRT410) with VL.
  • the amino acid sequence shown by SEQ ID NO: 26 is obtained by replacing all QQs in the amino acid sequence shown by SEQ ID NO: 7 with TS, and replacing the remaining Q with A.
  • the amino acid sequence shown by SEQ ID NO: 27 is obtained by replacing all QQs in the amino acid sequence shown by SEQ ID NO: 7 with VL, and replacing the remaining Q with I.
  • the amino acid sequence shown by SEQ ID NO:28 is obtained by substituting VI for all QQs in the amino acid sequence shown by SEQ ID NO:7 and L for the remaining Qs.
  • the amino acid sequence shown by SEQ ID NO: 29 is obtained by replacing all QQs in the amino acid sequence shown by SEQ ID NO: 7 with VF, and replacing the remaining Q with I.
  • the amino acid sequence shown by SEQ ID NO: 30 is obtained by replacing all QQs in the amino acid sequence shown by SEQ ID NO: 8 (Met-PRT525) with VL.
  • the amino acid sequence shown by SEQ ID NO: 31 is obtained by replacing all QQs in the amino acid sequence shown by SEQ ID NO: 8 with VL, and replacing the remaining Q with I.
  • the amino acid sequence represented by SEQ ID NO: 32 consists of 20 domain sequence regions present in the amino acid sequence represented by SEQ ID NO: 7 (Met-PRT410) that are repeated twice, and all QQ in the sequence are replaced with VF, And the remaining Q is replaced with I.
  • the amino acid sequence shown by SEQ ID NO: 41 (Met-PRT917) is obtained by replacing all QQs in the amino acid sequence shown by SEQ ID NO: 7 with LI and the remaining Qs with V.
  • the amino acid sequence shown by SEQ ID NO:42 (Met-PRT1028) is obtained by replacing all QQs in the amino acid sequence shown by SEQ ID NO:7 with IF, and replacing the remaining Q with T.
  • SEQ ID NO: 25 SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 41 and SEQ ID NO: 42 are all glutamine residues
  • the group content is below 9% (Table 2).
  • the artificial fibroin of (6-i) is SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 41 or SEQ ID NO: 42 It may consist of the amino acid sequence shown.
  • the artificial fibroin of (6-ii) is SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 41 or SEQ ID NO: 42 Amino acid sequences having 90% or greater sequence identity with the indicated amino acid sequences are included.
  • the artificial fibroin of (6-ii) also has a domain represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m -(A) n motif A protein containing a sequence.
  • the sequence identity is preferably 95% or more.
  • the artificial fibroin (6-ii) preferably has a glutamine residue content of 9% or less.
  • the artificial fibroin (6-ii) preferably has a GPGXX motif content of 10% or more.
  • the sixth artificial fibroin may contain a tag sequence at either or both of the N-terminus and C-terminus. This makes it possible to isolate, immobilize, detect and visualize artificial fibroin.
  • artificial fibroin containing a tag sequence examples include (6-iii) SEQ ID NO: 33 (PRT888), SEQ ID NO: 34 (PRT965), SEQ ID NO: 35 (PRT889), SEQ ID NO: 36 (PRT916), SEQ ID NO: 37 (PRT918), SEQ ID NO: 38 (PRT699), SEQ ID NO: 39 (PRT698), SEQ ID NO: 40 (PRT966), SEQ ID NO: 43 (PRT917) or SEQ ID NO: 44 (PRT1028) artificial fibroin comprising an amino acid sequence, or ( 6-iv) SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43 or SEQ ID NO: 44 and 90 Artificial fibroins comprising amino acid sequences with greater than % sequence identity can be mentioned.
  • amino acid sequences shown in SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43 and SEQ ID NO: 44 are SEQ ID NO: 25 , SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 41 and SEQ ID NO: 42 at the N-terminus of SEQ ID NO: 11
  • the amino acid sequence (including the His-tag sequence and hinge sequence) is added.
  • SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39 , SEQ ID NO: 40, SEQ ID NO: 43 and SEQ ID NO: 44 all have a glutamine residue content of 9% or less (Table 3).
  • the artificial fibroin of (6-iii) is SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43 or SEQ ID NO: 44 It may consist of the amino acid sequence shown.
  • (6-iv) artificial fibroin is SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43 or SEQ ID NO: 44 Amino acid sequences having 90% or greater sequence identity with the indicated amino acid sequences are included.
  • the artificial fibroin of (6-iv) also has a domain represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m -(A) n motif A protein containing a sequence.
  • the sequence identity is preferably 95% or more.
  • the artificial fibroin (6-iv) preferably has a glutamine residue content of 9% or less.
  • the artificial fibroin (6-iv) preferably has a GPGXX motif content of 10% or more.
  • the sixth artificial fibroin may contain a secretion signal for releasing the protein produced in the artificial protein production system to the outside of the host.
  • the sequence of the secretory signal can be appropriately set according to the type of host.
  • the artificial fibroin has at least two or more of the characteristics of the first artificial fibroin, the second artificial fibroin, the third artificial fibroin, the fourth artificial fibroin, the fifth artificial fibroin, and the sixth artificial fibroin. It may be an artificial fibroin having the characteristics of
  • the artificial fibroin according to this embodiment also has a domain sequence represented by Formula 1: [(A)n motif-REP]m or Formula 2: [(A)n motif-REP]m-(A)n motif It may be a protein containing
  • the artificial fibroin may further have an amino acid sequence (N-terminal sequence and C-terminal sequence) added to either or both of the N-terminal side and the C-terminal side of the domain sequence.
  • the N-terminal sequence and C-terminal sequence are typically, but not limited to, regions that do not have repeated amino acid motifs characteristic of fibroin and consist of about 100 amino acids.
  • domain sequence refers to a fibroin-specific crystalline region (typically corresponding to the (A) n motif of the amino acid sequence) and an amorphous region (typically corresponding to the REP of the amino acid sequence). ) and is represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m -(A) n motif means an array.
  • the (A) n motif represents an amino acid sequence composed of 4 to 27 amino acid residues, and the number of alanine residues is 80% or more of the total number of amino acid residues in the (A) n motif.
  • REP indicates an amino acid sequence composed of 10-200 amino acid residues.
  • n represents an integer of 10-300. m is preferably an integer of 20-300, more preferably an integer of 30-300.
  • a plurality of (A) n motifs may have the same amino acid sequence or different amino acid sequences.
  • a plurality of REPs may have the same amino acid sequence or different amino acid sequences.
  • At least seven of the (A) n motifs present in the domain sequence are preferably composed only of alanine residues. Consisting only of alanine residues means that the (A) n motif has an amino acid sequence represented by (Ala) k (Ala represents an alanine residue). k is preferably an integer of 4-27, more preferably an integer of 4-20, and still more preferably an integer of 4-16.
  • REP is composed of 10 to 200 amino acid residues.
  • One or more of the amino acid residues constituting REP may be amino acid residues selected from the group consisting of glycine residues, serine residues, and alanine residues. That is, REP may contain amino acid residues selected from the group consisting of glycine residues, serine residues, and alanine residues.
  • One or more of the amino acid residues constituting REP may be hydrophobic amino acid residues. That is, REP preferably contains hydrophobic amino acid residues.
  • a hydrophobic amino acid residue means an amino acid residue with a positive hydrophobicity index.
  • hydrophobicity index of amino acid residues hydrophobicity index, hereinafter also referred to as "HI"
  • HI hydrophobicity index
  • Hydrophobic amino acid residues include, for example, isoleucine (HI: 4.5), valine (HI: 4.2), leucine (HI: 3.8), phenylalanine (HI: 2.8), methionine (HI: 1.9) and alanine (HI: 1.8).
  • the domain sequence preferably has an amino acid sequence corresponding to the insertion of a cysteine residue into REP, as compared with naturally occurring fibroin.
  • the domain sequence preferably has an amino acid sequence corresponding to the insertion of a cysteine residue at a position adjacent to a glycine residue, a serine residue, or an alanine residue in REP. More preferably, it has an amino acid sequence corresponding to a cysteine residue inserted at a position adjacent to the glycine residue.
  • a cysteine residue in REP may be located between a glycine residue, a serine residue, or an alanine residue and a glycine residue, a serine residue, or an alanine residue; residues.
  • the domain sequence preferably has an amino acid sequence corresponding to the insertion of a cysteine residue at the position adjacent to the hydrophobic amino acid residue in REP.
  • hydrophobic amino acid residues are fixed between molecules by hydrophobic interaction.
  • a cysteine residue in REP may be positioned next to a hydrophobic amino acid residue, or may be positioned between a hydrophobic amino acid residue and an amino acid residue other than a hydrophobic amino acid residue.
  • a hydrophobic amino acid residue and a glycine residue, a serine residue, or an alanine residue and may be positioned between a hydrophobic amino acid residue and a glycine residue.
  • Hydrophobic amino acid residues may be one selected from the group consisting of isoleucine residues, valine residues, leucine residues, phenylalanine residues, methionine residues, and alanine residues.
  • the domain sequence has an amino acid sequence corresponding to the insertion of a cysteine residue into the REP located near the N-terminus and/or C-terminus of the domain sequence compared to naturally-occurring fibroin. good.
  • the molecular chain can be lengthened.
  • a REP located near the N-terminus of a domain sequence means a REP located 1st to 3rd from the N-terminus of the domain sequence.
  • a cysteine residue may be located in the REP positioned 1-2 from the N-terminus of the domain sequence.
  • a REP located near the C-terminus of a domain sequence means a REP located 1st to 3rd from the C-terminus of the domain sequence.
  • a cysteine residue may be located in the REP positioned 1-2 from the C-terminus of the domain sequence.
  • Cysteine residues are preferably located in the most N-terminal and/or most C-terminal REP of the domain sequence.
  • the domain sequence may have an amino acid sequence corresponding to the insertion of a cysteine residue at or near the center in REP compared to naturally occurring fibroin.
  • the vicinity of the center of the amino acid sequence in REP refers to the amino acid residue located in the center of REP (when there are two amino acid residues located in the center, the amino acid residue on the N-terminal side) to N 1st to 5th positions toward the terminal side, or 1st to 5th amino acid residues located in the center of REP (when there are two amino acid residues located in the center, amino acid residues on the C-terminal side) indicates the position of
  • the cysteine residue may be located in the center of REP, and is located at the 1st to 3rd or 1st to 2nd positions toward the N-terminal side or the C-terminal side from the amino acid residue located in the center of REP. You may have
  • the artificial fibroin preferably contains a GPGXX motif (G represents a glycine residue, P represents a proline residue, and X represents an amino acid residue other than a glycine residue) in the amino acid sequence of REP. Inclusion of this motif in REP can improve the elongation of the artificial fibroin.
  • the GPGXX motif content is usually 1% or more, may be 5% or more, and preferably 10% or more. In this case, the stress of the artificial fibroin fiber becomes even higher.
  • the upper limit of the GPGXX motif content is not particularly limited, and may be 50% or less, or 30% or less.
  • the "GPGXX motif content” is a value calculated by the following method.
  • Formula 1 [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m -(A) n motif, the most C-terminal In all REPs contained in the sequence excluding the sequence from the located (A) n motif to the C-terminus of the domain sequence from the domain sequence, triple the total number of GPGXX motifs contained in that region (i.e., (corresponding to the total number of G and P in the GPGXX motif) is c, the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence is removed from the domain sequence, and the (A) n motif is further removed.
  • the GPGXX motif content is calculated as c/d, where d is the total number of amino acid residues in all REPs removed.
  • the "sequence obtained by removing the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence from the domain sequence” is "the most C-terminal side (A)
  • the sequence from the n motif to the C-terminus of the domain sequence” may include sequences that are poorly correlated with sequences characteristic of fibroin, and m is small If the domain sequence is short (that is, if the domain sequence is short), it affects the calculation result of the GPGXX motif content rate, so this effect is to be eliminated.
  • a "GPGXX motif” is located at the C-terminus of REP, it is treated as a "GPGXX motif” even if "XX" is, for example, "AA”.
  • FIG. 6 is a schematic diagram showing the domain sequence of fibroin.
  • Artificial fibroin has a REP hydrophobicity (hydropathy index: hydrophobicity index) of, for example, -0.80, -0.70, -0.06 or more, -0.50 or more, -0.40 or more. , -0.30 or more, -0.20 or more, -0.10 or more, 0.00 or more, 0.10 or more, 0.20 or more, 0.22 or more, 0.25 or more, 0.30 or more, 0 0.35 or greater, 0.40 or greater, 0.45 or greater, 0.50 or greater, 0.55 or greater, 0.60 or greater, 0.65 or greater, or 0.70 or greater.
  • hydrophobicity of REP There is no particular upper limit to the hydrophobicity of REP, and it may be 1.0 or less, or 0.7 or less.
  • the "hydrophobicity of REP” is a value calculated by the following method.
  • Formula 1 [(A) n motif-REP] m or
  • Formula 2 [(A) n motif-REP] m -(A) n motif, the most C-terminal In all REPs contained in the sequence obtained by excluding the sequence from the located (A) n motif to the C-terminus of the domain sequence from the domain sequence (sequence corresponding to “region A” in FIG.
  • each amino acid in the region The sum of the hydrophobicity indices of the residues is e, the sequence from the (A) n motif located on the most C-terminal side to the C-terminus of the domain sequence is removed from the domain sequence, and all REPs excluding the (A) n motif
  • the hydrophobicity of REP is calculated as e/f, where f is the total number of amino acid residues in .
  • the reason for targeting is the reason described above. It is the same.
  • the molecular weight of the artificial fibroin according to this embodiment is not particularly limited, it may be, for example, 10 kDa or more and 700 kDa or less.
  • the molecular weight of the artificial fibroin according to the present embodiment is, for example, 2 kDa or more, 3 kDa or more, 4 kDa or more, 5 kDa or more, 6 kDa or more, 7 kDa or more, 8 kDa or more, 9 kDa or more, 10 kDa or more, 20 kDa or more, 30 kDa or more, 40 kDa or more, 50 kDa.
  • the artificial fibroin (i) may have only the amino acid sequence shown in SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, or SEQ ID NO: 51.
  • the artificial fibroin of (ii) may have only the amino acid sequence shown in SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, or SEQ ID NO:55.
  • the artificial fibroin described above may contain a tag sequence at either or both of the N-terminus and C-terminus. This enables isolation, immobilization, detection, visualization, etc. of artificial fibroin.
  • tag sequences include affinity tags that utilize specific affinity (binding, affinity) with other molecules.
  • affinity tag is a histidine tag (His tag).
  • His tag is a short peptide in which about 4 to 10 histidine residues are lined up, and because it has the property of specifically binding to metal ions such as nickel, artificial fibroin is isolated by metal chelating chromatography.
  • a specific example of the tag sequence is the amino acid sequence represented by SEQ ID NO: 70 or SEQ ID NO: 71 (amino acid sequence containing a His tag).
  • tag sequences such as glutathione-S-transferase (GST) that specifically binds to glutathione and maltose binding protein (MBP) that specifically binds to maltose can be used.
  • GST glutathione-S-transferase
  • MBP maltose binding protein
  • epitope tags that utilize antigen-antibody reactions. By adding an antigenic peptide (epitope) as a tag sequence, an antibody against the epitope can be bound.
  • epitope tags include HA (peptide sequence of influenza virus hemagglutinin) tag, myc tag, FLAG tag, and the like. Artificial fibroin can be easily purified with high specificity by using an epitope tag.
  • a tag sequence that can be cleaved by a specific protease can also be used.
  • Artificial fibroin from which the tag sequence has been cut off can also be recovered by treating the protein adsorbed via the tag sequence with protease.
  • artificial fibroin containing a tag sequence examples include (iii) SEQ ID NO: 60 (PRT15), SEQ ID NO: 61 (PRT16), SEQ ID NO: 62 (PRT17), SEQ ID NO: 63 (PRT18), SEQ ID NO: 64 (PRT19) ), or an artificial fibroin comprising the amino acid sequence shown in SEQ ID NO: 65 (PRT20), or (iv) SEQ ID NO: 66 (PRT21), SEQ ID NO: 67 (PRT22), SEQ ID NO: 68 (PRT23), or SEQ ID NO: 69 ( Artificial fibroin containing the amino acid sequence shown in PRT24) can be mentioned.
  • amino acid sequences represented by SEQ ID NO: 60 (PRT15), SEQ ID NO: 61 (PRT16), SEQ ID NO: 62 (PRT17), SEQ ID NO: 63 (PRT18), SEQ ID NO: 64 (PRT19), and SEQ ID NO: 65 (PRT20) are , SEQ ID NO: 46 (PRT1), SEQ ID NO: 47 (PRT2), SEQ ID NO: 48 (PRT3), SEQ ID NO: 49 (PRT4), SEQ ID NO: 50 (PRT5), and SEQ ID NO: 51 (PRT6), respectively.
  • a tag sequence containing the amino acid sequence shown in SEQ ID NO: 70 is introduced at the N-terminus of .
  • amino acid sequences shown in SEQ ID NO: 66 are SEQ ID NO: 52 (PRT7) and SEQ ID NO: 53 ( PRT8), SEQ ID NO: 54 (PRT9), and SEQ ID NO: 55 (PRT10) with a tag sequence including the amino acid sequence of SEQ ID NO: 70 introduced at the N-terminus.
  • the artificial fibroin of (iii) may have only the amino acid sequence shown in SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.
  • SEQ ID NO: 60 (PRT15), SEQ ID NO: 61 (PRT16), SEQ ID NO: 62 (PRT17), SEQ ID NO: 63 (PRT18), SEQ ID NO: 64 (PRT19), or SEQ ID NO: 65 (PRT20)
  • the GPGXX motif content of the artificial fibroin is 40.2%, 39.9%, 39.9%, 39.7%, 39.3%, and 38.6%, respectively, all of which are 10% or more. .
  • the artificial fibroin may have only the amino acid sequence shown in SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, or SEQ ID NO: 69.
  • the GPGXX motif content of the artificial fibroin containing the amino acid sequence shown in SEQ ID NO: 66 (PRT21), SEQ ID NO: 67 (PRT22), SEQ ID NO: 68 (PRT23), or SEQ ID NO: 69 (PRT24) is 39.9%, respectively. , 39.9%, 39.3%, and 38.6%, all of which are 10% or more.
  • the artificial fibroin described above may contain a secretion signal for releasing the protein produced in the recombinant protein production system to the outside of the host.
  • the sequence of the secretory signal can be appropriately set according to the type of host.
  • a nucleic acid encodes the artificial fibroin.
  • nucleic acids are amino acids represented by SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55
  • Nucleic acids are included.
  • a nucleic acid hybridizes under stringent conditions to a complementary strand of the artificial fibroin-encoding nucleic acid, and has formula 1: [(A) n motif-REP] m or formula 2: [( A) n -motif-REP] m -(A)
  • a nucleic acid encoding an artificial fibroin comprising a domain sequence represented by the n- motif.
  • the above domain sequence of the artificial fibroin encoded by the nucleic acid has an amino acid sequence corresponding to the insertion of a cysteine residue into REP, compared to naturally-occurring fibroin.
  • “Stringent conditions” refer to conditions under which so-called specific hybrids are formed and non-specific hybrids are not formed. “Stringent conditions” may be any of low stringent conditions, medium stringent conditions and high stringent conditions. Low stringency conditions means that hybridization occurs only when there is at least 85% or more identity between the sequences. Conditions for hybridization include: Moderately stringent conditions means that hybridization occurs only when there is at least 90% identity between the sequences, for example, using 5xSSC containing 0.5% SDS at 50°C. Conditions for hybridization include: High stringency conditions means that hybridization occurs only when there is at least 95% or more identity between the sequences. Conditions for hybridization include:
  • An expression vector comprises the nucleic acid sequence described above and one or more regulatory sequences operably linked to the nucleic acid sequence.
  • a regulatory sequence is a sequence that controls expression of a recombinant protein in a host (eg, promoter, enhancer, ribosome binding sequence, transcription termination sequence, etc.), and can be appropriately selected according to the type of host.
  • the type of expression vector can be appropriately selected from plasmid vectors, virus vectors, cosmid vectors, fosmid vectors, artificial chromosome vectors, etc., depending on the type of host.
  • a host according to one embodiment is transformed with the above expression vector.
  • hosts both prokaryotes and eukaryotes such as yeast, filamentous fungi, insect cells, animal cells and plant cells can be suitably used.
  • those capable of autonomous replication in host cells or capable of integration into the chromosome of the host and containing a promoter at a position at which the nucleic acid according to one embodiment can be transcribed are preferably used.
  • the expression vector according to one embodiment is capable of autonomous replication in the prokaryote, and at the same time includes a promoter, a ribosome binding sequence, a nucleic acid according to one embodiment, and a transcription termination sequence. It is preferably a vector containing A gene controlling a promoter may be included.
  • prokaryotes examples include microorganisms belonging to the genera Escherichia, Brevibacillus, Serratia, Bacillus, Microbacterium, Brevibacterium, Corynebacterium, and Pseudomonas.
  • microorganisms belonging to the genus Escherichia include Escherichia coli BL21 (Novagen), Escherichia coli BL21 (DE3) (Life Technologies), Escherichia coli BLR (DE3) (Merck Millipore), Escherichia coli DH1, Escherichia ⁇ Coli GI698, Escherichia coli HB101, Escherichia coli JM109, Escherichia coli K5 (ATCC 23506), Escherichia coli KY3276, Escherichia coli MC1000, Escherichia coli MG1655 (ATCC 47076), Escherichia coli No.
  • Escherichia coli Rosetta (DE3) (Novagen), Escherichia coli TB1, Escherichia coli Tuner (Novagen), Escherichia coli Tuner (DE3) (Novagen), Escherichia coli W1485, Escherichia coli W3110 ( ATCC 27325), Escherichia coli XL1-Blue, and Escherichia coli XL2-Blue.
  • microorganisms belonging to the genus Brevibacillus include Brevibacillus agri, Brevibacillus borsterensis, Brevibacillus centropolus Brevibacillus formosus, Brevibacillus imvocatus, Brevibacillus latyrosporus, Brevibacillus limnophilus, Brevibacillus parabrevis , Brevibacillus reuszeri, Brevibacillus thermoluvar, Brevibacillus brevis 47 (FERM BP-1223), Brevibacillus brevis 47K (FERM BP-2308), Brevibacillus brevis 47-5 (FERM BP-1664), Brevibacillus brevis Bacillus brevis 47-5Q (JCM8975), Brevibacillus choshinensis HPD31 (FERM BP-1087), Brevibacillus choshinensis HPD31-S (FERM BP-6623), Brevibacillus a
  • microorganisms belonging to the genus Serratia include Serratia liquefaciens ATCC14460, Serratia entomophila, Serratia ficaria, Serratia fonticola, and Serratia grimesi. (Serratia grimesii), Serratia proteamaculans, Serratia odorifera, Serratia polymuthica, and Serratia rubidae.
  • microorganisms belonging to the genus Bacillus include Bacillus subtilis and Bacillus amyloliquefaciens.
  • microorganisms belonging to the genus Microbacterium include Microbacterium Ammoniaphyllum ATCC15354.
  • microorganisms belonging to the genus Brevibacterium include, for example, Brevibacterium divericatum (Corynebacterium glutamicum) ATCC14020, Brevibacterium flavum (Corynebacterium glutamicum ATCC14067) ATCC13826, ATCC14067, Brevibacterium inmariophyllum (Brevibacterium immariophilum)ATCC14068 ⁇ ( ⁇ ATCC13869)ATCC13665,ATCC13869 ⁇ ATCC13825 ⁇ (Brevibacterium saccharolyticum)ATCC14066 ⁇ thiogenitalis ATCC19240, Brevibacterium album ATCC15111, and Brevibacterium serinum ATCC15112.
  • Examples of microorganisms belonging to the genus Corynebacterium include Corynebacterium ammoniagenes ATCC6871 and ATCC6872, Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC14067, and Corynebacterium glutamicum ATCC14067. ⁇ (Corynebacterium acetoacidophilum)ATCC13870 ⁇ ATCC15806 ⁇ ATCC21511 ⁇ ATCC15991 ⁇ ATCC13020,ATCC13032,ATCC13060 ⁇ ATCC15990 ⁇ Corynebacterium melasecola ATCC17965, Corynebacterium thermoaminogenes AJ12340 (FERMBP-1539), Corynebacterium herculis ATCC13868, and the like.
  • microorganisms belonging to the genus Pseudomonas include Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas brassicacearum, Pseudomonas brassicacerum, Pseudomonas fulva, and Pseudomonas Pseudomonas. (Pseudomonas sp.) D-0110 and the like.
  • Any method for introducing DNA into the host cell can be used as the method for introducing the expression vector into the host cell.
  • a method using calcium ions [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)], the protoplast method (JP-A-63-248394), or the methods described in Gene, 17, 107 (1982) and Molecular & General Genetics, 168, 111 (1979).
  • JP-A-63-248394 protoplast method
  • Transformation of microorganisms belonging to the genus Brevibacillus for example, the method of Takahashi et al. (J. Bacteriol., 1983, 156: 1130-1134) and the method of Takagi et al. -3100), or the method of Okamoto et al. (Biosci. Biotechnol. Biochem., 1997, 61: 202-203).
  • vectors for introducing a nucleic acid according to one embodiment include pBTrp2, pBTac1, and pBTac2 (all commercially available from Boehringer Mannheim), pKK233-2 (manufactured by Pharmacia), and pSE280. (manufactured by Invitrogen), pGEMEX-1 (manufactured by Promega), pQE-8 (manufactured by QIAGEN), pKYP10 (Japanese Patent Application Laid-Open No. 58-110600), pKYP200 [Agric. Biol. Chem.
  • suitable vectors include, for example, pUC18, pBluescriptII, pSupex, pET22b, and pCold.
  • vectors suitable for microorganisms belonging to the genus Brevibacillus include pUB110, which is known as a Bacillus subtilis vector, or pHY500 (JP-A-2-31682), pNY700 (JP-A-4-278091), pHY4831 (J Bacteriol., 1987, 1239-1245), pNU200 (Shigezo Udaka, Journal of Japan Agricultural Chemistry 1987, 61: 669-676), pNU100 (Appl. Microbiol. Biotechnol., 1989, 30: 75-80), pNU211 (J. Biochem., 1992, 112: 488-491), pNU211R2L5 (JP-A-7-170984), pNH301 (Appl.
  • the promoter is not limited as long as it functions in the host cell. Examples thereof include promoters derived from Escherichia coli, phage, etc., such as trp promoter (Ptrp), lac promoter, PL promoter, PR promoter, and T7 promoter. In addition, artificially designed and modified promoters such as a promoter in which two Ptrps are arranged in series (Ptrp ⁇ 2), tac promoter, lacT7 promoter, let I promoter, and the like can also be used.
  • a transcription termination sequence is not necessarily required for expression of the above nucleic acid, but it is preferred to place a transcription termination sequence directly under the structural gene.
  • Examples of eukaryotic hosts include yeast, filamentous fungi (molds, etc.), and insect cells.
  • yeast for example, the genus Saccharomyces, the genus Schizosaccharomyces, the genus Kluyveromyces, the genus Trichosporon, the genus Schwanniomyces, the genus Pichia, the genus Candida , yeast belonging to the genus Yarrowia and Hansenula. ⁇ (Saccharomyces cerevisiae) ⁇ (Schizosaccharomyces pombe) ⁇ (Kluyveromyces lactis) ⁇ (Kluyveromyces marxianus) ⁇ (Trichosporon pullulans) ⁇ Schwanniomyces alluvius, Schwanniomyces occidentalis, Candida utilis, Pichia pastoris, Pichia angusta, Pichia morpha Pichia Pichiola (Pichia polymorpha), Pichia stipitis, Yarrowia lipolytica, and Hansenula polymorpha.
  • the expression vector When yeast is used as a host cell, the expression vector usually contains an origin of replication (if amplification in the host is required) and a selectable marker for propagation of the vector in E. coli, a promoter for recombinant protein expression in yeast, and a It is preferred to include a terminator as well as a selectable marker for yeast.
  • the expression vector when it is a non-integrating vector, it preferably further contains an autonomously replicating sequence (ARS). This can improve the stability of the expression vector in cells (Myers, AM, et al. (1986) Gene 45:299-310).
  • ARS autonomously replicating sequence
  • yeast examples include YEp13 (ATCC37115), YEp24 (ATCC37051), YCp50 (ATCC37419), YIp, pHS19, pHS15, pA0804, pHIL3Ol, pHIL-S1, pPIC9K, pPICZ ⁇ , pGAPZ ⁇ , and pPICZ B etc. can be mentioned.
  • the promoter is not limited as long as it can be expressed in yeast.
  • promoters include promoters of glycolytic genes such as hexose kinase, PHO5 promoter, PGK promoter, GAP promoter, ADH promoter, gal1 promoter, gal10 promoter, heat shock polypeptide promoter, MF ⁇ 1 promoter, and CUP1 promoter. , pGAP promoter, pGCW14 promoter, AOX1 promoter, and MOX promoter.
  • Any method for introducing DNA into yeast can be used as a method for introducing an expression vector into yeast.
  • methods for introducing expression vectors into yeast include electroporation (Methods Enzymol., 194, 182 (1990)), spheroplast method (Proc. Natl. Acad. Sci., USA, 81, 4889 ( 1984)), the lithium acetate method (J. Bacteriol., 153, 163 (1983)), and Proc. Natl. Acad. Sci. USA, 75, 1929 (1978), and the like.
  • filamentous fungi examples include Acremonium genus, Aspergillus genus, Ustilago genus, Trichoderma genus, Neurospora genus, Fusarium genus, Humicola genus, Penicillium genus, Myceliophtora genus, Botryts genus, Magnaporthe genus, Mucor genus, Metalhizium genus, Monascus genus, Rhizopus genus , and bacteria belonging to the genus Rhizomucoa.
  • filamentous fungi include Acremonium alabamense, Acremonium cellulolyticus, Aspergillus aculeatus, Aspergillus awamori, Aspergillus awamori Aspergillus oryzae) ⁇ (Aspergillus sake) ⁇ ( ⁇ )(Aspergillus sojae) ⁇ (Aspergillus tubigensis) ⁇ (Aspergillus niger) ⁇ (Aspergillus nidulans) ⁇ (Aspergillus parasiticus) ⁇ ( ⁇ )(Aspergillus ficuum) ⁇ (Aspergillus phoeicus) ⁇ ( ⁇ )(Aspergillus foetidus) ⁇ (Aspergillus flavus) ⁇ (Aspergillus fumigatus ) ⁇ ( ⁇ )(Aspergillus japonicus) ⁇ (Trichoderma viride) ⁇ (Trichoderma harzianum) ⁇ (Trichoderma reseei) ⁇ (Chry
  • the promoter may be a gene related to glycolysis, a gene related to constitutive expression, an enzyme gene related to hydrolysis, or the like.
  • Specific examples of promoters when the host is a filamentous fungus include amyB, glaA, agdA, glaB, TEF1, xynF1tannasegene, No. 8AN, gpdA, pgkA, enoA, melO, sodM, catA, and catB, and the like.
  • Methods for introducing expression vectors into filamentous fungi include, for example, the method of Cohen et al. (calcium chloride method) [Proc. Natl. Acad. Sci. USA, 69:2110 (1972)], protoplast method [Mol. Gen. Genet. , 168:111 (1979)], competent methods [J. Mol. Biol. , 56:209 (1971)], electroporation, and the like.
  • Insect cells include, for example, Lepidoptera insect cells. More specifically, insect cells include Spodoptera frugiperda-derived insect cells such as Sf9 and Sf21, and Trichoplusia ni-derived insect cells such as High 5. .
  • Baculovirus Expression Vectors such as Autographa californica nuclear polyhedrosis virus, which is a virus that infects insects of the family Mothidae. , A Laboratory Manual, WH Freeman and Company, New York (1992)).
  • Methods for co-introducing a recombinant gene transfer vector and baculovirus into insect cells for preparing a recombinant virus include, for example, the calcium phosphate method (JP-A-2-227075) and the lipofection method (Proc. Natl. Acad.Sci.USA, 84, 7413 (1987)).
  • a recombinant vector according to one embodiment preferably further contains a selection marker gene for transformant selection.
  • a selection marker gene for transformant selection For example, in E. coli, resistance genes to various drugs such as tetracycline, ampicillin, and kanamycin can be used as selectable marker genes. Recessive selectable markers that can complement genetic mutations involved in auxotrophy can also be used. In yeast, genes resistant to geneticin can be used as selectable marker genes, and selectable markers such as LEU2, URA3, TRP1, and HIS3, genes that complement gene mutations involved in auxotrophy can also be used. In filamentous fungi, selectable marker genes include niaD (Biosci. Biotechnol.
  • a host transformed with an expression vector according to one embodiment can be selected by plaque hybridization, colony hybridization, or the like using a probe that selectively binds to the nucleic acid.
  • a probe that selectively binds to the nucleic acid.
  • a partial DNA fragment amplified by PCR based on the sequence information of the above nucleic acid and modified with a radioisotope or digoxigenin can be used.
  • Artificial fibroin can be produced by a method comprising the step of expressing the above nucleic acid in a host transformed with the above expression vector.
  • the expression method in addition to direct expression, secretory production, fusion protein expression, etc. can be performed according to the method described in Molecular Cloning, Second Edition.
  • artificial fibroin When expressed in yeast, animal cells, or insect cells, artificial fibroin can be obtained as a polypeptide to which a sugar or sugar chain has been added.
  • Artificial fibroin can be produced, for example, by culturing a host transformed with the expression vector in a culture medium, producing and accumulating the artificial fibroin according to the present embodiment in the culture medium, and collecting the artificial fibroin from the culture medium. can be done.
  • the method of culturing the host in the culture medium can be carried out according to a method commonly used for culturing the host.
  • the culture medium for the host contains a carbon source, a nitrogen source, an inorganic salt, etc. that can be assimilated by the host, Either a natural medium or a synthetic medium may be used as long as the medium can efficiently perform the above.
  • Carbon sources include carbohydrates such as glucose, fructose, sucrose, and molasses containing these, starch and starch hydrolysates, organic acids such as acetic acid and propionic acid, and alcohols such as ethanol and propanol. can be done.
  • Nitrogen sources include, for example, ammonia, ammonium chloride, ammonium sulfate, ammonium salts of inorganic or organic acids such as ammonium acetate and ammonium phosphate, other nitrogen-containing compounds, peptone, meat extract, yeast extract, corn steep liquor, Casein hydrolysates, soybean meal and soybean meal hydrolysates, various fermented cells and their digests can be used.
  • potassium dibasic phosphate dibasic potassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, and calcium carbonate
  • inorganic salts for example, potassium dibasic phosphate, dibasic potassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, and calcium carbonate can be used.
  • Prokaryotes such as E. coli or eukaryotes such as yeast can be cultured under aerobic conditions such as shaking culture or deep aeration stirring culture.
  • the culture temperature is, for example, 15-40°C.
  • Culture time is usually 16 hours to 7 days.
  • the pH of the culture medium during cultivation is preferably maintained between 3.0 and 9.0.
  • the pH of the culture medium can be adjusted using inorganic acids, organic acids, alkaline solutions, urea, calcium carbonate, ammonia, and the like.
  • antibiotics such as ampicillin and tetracycline may be added to the culture medium as necessary during the culture.
  • an inducer may be added to the medium as necessary.
  • isopropyl- ⁇ -D-thiogalactopyranoside or the like is used when culturing a microorganism transformed with an expression vector using a lac promoter, and indole acrylic when culturing a microorganism transformed with an expression vector using a trp promoter. Acids and the like may be added to the medium.
  • Culture media for insect cells include, for example, commonly used TNM-FH medium (manufactured by Pharmingen), Sf-900 II SFM medium (manufactured by Life Technologies), ExCell400, ExCell405 (both manufactured by JRH Biosciences), and Grace's Insect Medium (Nature, 195, 788 (1962)).
  • Insect cells can be cultured for 1 to 5 days under conditions such as a culture medium with a pH of 6 to 7 and a culture temperature of 25 to 30°C.
  • antibiotics such as gentamicin may be added to the culture medium as necessary during the culture.
  • the transformed plant cell can be cultured as it is, or it can be differentiated into plant organs and cultured.
  • the medium for culturing the plant cells include commonly used Murashige and Skoog (MS) medium, White medium, or these medium supplemented with plant hormones such as auxin and cytokinin. can be used.
  • Animal cells can be cultured for 3 to 60 days under conditions such as a culture medium with a pH of 5 to 9 and a culture temperature of 20 to 40°C. Moreover, antibiotics such as kanamycin and hygromycin may be added to the medium as necessary during the culture.
  • Methods of producing artificial fibroin using a host transformed with the expression vector include a method of producing the artificial fibroin in the host cell, a method of secreting the artificial fibroin outside the host cell, and a method of producing it on the extracellular membrane of the host cell. There are methods, etc. Each of these methods can be selected by varying the host cell used and the structure of the artificial fibroin produced.
  • artificial fibroin when artificial fibroin is produced in the host cell or on the host cell extracellular membrane, the method of Paulson et al. USA, 86, 8227 (1989), Genes Develop., 4, 1288 (1990)), or by applying the methods described in JP-A-5-336963, WO 94/23021, etc. , can be modified to actively secrete artificial fibroin out of host cells. That is, artificial fibroin can be actively secreted outside the host cell by expressing a polypeptide containing the active site of artificial fibroin with a signal peptide added thereto using a genetic recombination technique.
  • Artificial fibroin produced by a host transformed with the above expression vector can be isolated and purified by methods commonly used for protein isolation and purification. For example, when artificial fibroin is expressed in a dissolved state in cells, the host cells are recovered by centrifugation after the completion of culture, suspended in an aqueous buffer, and then subjected to an ultrasonic crusher, a French press, or a Manton. The host cells are disrupted with a Gaulin homogenizer, Dynomill, or the like to obtain a cell-free extract.
  • a method commonly used for protein isolation and purification that is, a solvent extraction method, a salting-out method using ammonium sulfate, etc., a desalting method, an organic solvent Precipitation method, diethylaminoethyl (DEAE)-Sepharose, DIAION HPA-75 (manufactured by Mitsubishi Kasei) and other resins, anion exchange chromatography, S-Sepharose FF (Pharmacia) and other resins, etc.
  • a solvent extraction method a salting-out method using ammonium sulfate, etc.
  • a desalting method an organic solvent Precipitation method
  • diethylaminoethyl (DEAE)-Sepharose diethylaminoethyl
  • DIAION HPA-75 manufactured by Mitsubishi Kasei
  • anion exchange chromatography S-Sepharose FF (Pharmacia) and other resins, etc.
  • Ion exchange chromatography hydrophobic chromatography using resins such as butyl sepharose and phenyl sepharose, gel filtration using molecular sieves, affinity chromatography, chromatofocusing, and electrophoresis such as isoelectric focusing
  • a purified sample can be obtained by using the methods such as the above alone or in combination.
  • the host cells are similarly collected, crushed, and centrifuged to collect the insoluble form of the artificial fibroin as a precipitate fraction.
  • the collected insoluble artificial fibroin can be solubilized with a protein denaturant. After this operation, a purified preparation of artificial fibroin can be obtained by the same isolation and purification method as described above.
  • the artificial fibroin or its derivative can be recovered from the culture supernatant. That is, a culture supernatant is obtained by treating the culture by a technique such as centrifugation, and a purified preparation can be obtained from the culture supernatant by using the same isolation and purification method as described above.
  • Binder Any type of binder can be used as long as it is a high-molecular polymer such as protein, peptide, polysaccharide, oligosaccharide, sugar polymer, fatty acid, fatty acid polymer, or polyphenol. These binders may or may not have the property of adhering to raw material fibers.
  • the "property of adhering” is the property of binding different types of substances when they are brought close to each other by interaction, and includes "wetting” and "aggregation”. The interaction is also called van der Waals force, surface tension, interfacial tension, electrostatic interaction, and the like.
  • the adhesive binder immobilizes the bundle of the raw material fibers by enzymatic reaction to crosslink the binder and the raw material fibers, or between the binders, forming large-diameter artificial polypeptide fibers.
  • the non-adhesive binder is prepared by bundling the raw material fibers in a cylindrical container or the like, and then by enzymatic reaction to cross-link the binder and the raw material fibers, or between the binders to fix the bundle of the raw material fibers, resulting in a large diameter. Form artificial polypeptide fibers.
  • Adhesive binders include polypeptides, peptides, proteins, polysaccharides, phenolic compounds, preferably fibroin (including natural and artificial), gelatin, collagen, casein glue, starch, kraft lignin, viscous polysaccharides. is mentioned.
  • non-adhesive binders examples include polypeptides, peptides, phenolic compounds, and polysaccharides.
  • the polypeptide or peptide is preferably a polypeptide or peptide containing either tyrosine, lysine or cysteine.
  • Phenolic compounds are preferably polyphenols, and polysaccharides are preferably polysaccharides to which phenols are bound (eg, sugar beet pectin, etc.).
  • the amount of the binder used may be 0.001 to 10000% by mass, based on the mass of the raw material fiber. It is preferably 100% by mass, or 3 to 30% by mass.
  • the enzyme used in the present embodiment may be any enzyme that can recognize at least one of the raw material fiber and the binder as a substrate for the enzyme, and may be an oxidoreductase or a protein cross-linking enzyme.
  • Cross-linking enzymes also include acyltransferases and oxidoreductases.
  • protein cross-linking enzymes examples include polyphenol oxidase (tyrosinase), peroxidase, multi-copper oxidase (laccase, bilirubin oxidase, ascorbic acid oxidase, ceruloplasmin), transglutaminase, lysyl oxidase, protein disulfide isomerase, protein disulfide reductase, sulfhydryl oxidase. , lipoxygenase.
  • polyphenol oxidase tyrosinase
  • peroxidase multi-copper oxidase
  • laccase laccase
  • bilirubin oxidase ascorbic acid oxidase
  • ceruloplasmin ceruloplasmin
  • transglutaminase lysyl oxidase
  • protein disulfide isomerase protein disulfide reductase
  • the protein cross-linking enzyme is preferably an oxidoreductase, and specific examples include polyphenol oxidase (tyrosinase), peroxidase, multicopper oxidase (laccase, bilirubin oxidase, ascorbic acid oxidase, ceruloplasmin), lysyl oxidase, and sulfhydryl oxidase. be done. More preferred are laccase, bilirubin oxidase, peroxidase and tyrosinase, and still more preferred are laccase, bilirubin oxidase and peroxidase.
  • More preferred enzymes are, for example, laccase, bilirubin oxidase, and combined use of peroxidase and glucose oxidase.
  • the oxidoreductase is not particularly limited as long as it can generate a reactive functional group (eg, aldehyde) by oxidizing or reducing the chemical structure of at least one of the binder and raw fiber.
  • a reactive functional group eg, aldehyde
  • Examples of oxidoreductases include the following.
  • Enzymes with low substrate specificity and containing metal ions in the active center for example, multi-copper oxidases such as laccase
  • an enzyme that oxidizes the ⁇ -amino group of a lysine residue in a protein to produce an aldehyde group eg, lysyl oxidase
  • Enzymes that oxidize sulfhydryl groups of cysteine residues in proteins e.g., sulfhydryl oxidase
  • Enzymes that require hydrogen peroxide as an oxygen donor in oxidation reactions for example, peroxidase, which may be used in combination with glucose oxidase to generate hydrogen peroxide
  • multi-copper oxidase is a group of enzymes that have a copper atom in the active center, extract (oxidize) electrons from various substrates such as polyphenols, methoxyphenols, diamines, bilirubin, and ascorbic acid, and reduce molecular oxygen.
  • substrates such as polyphenols, methoxyphenols, diamines, bilirubin, and ascorbic acid
  • Multicopper oxidases include, for example, laccase, bilirubin oxidase, ascorbate oxidase, ceruloplasmin and the like.
  • binder and enzyme are, for example, polypeptide and laccase, polyphenol and laccase, polypeptide and bilirubin oxidase, polypeptide and peroxidase, polypeptide and peroxidase and glucose oxidase, more preferably silk fibroin and laccase, silk fibroin and bilirubin oxidase, silk fibroin and peroxidase, silk fibroin and peroxidase and glucose oxidase, gelatin and laccase.
  • Non-Patent Document 1 Conventionally, cross-linking and adhesion of binders (especially proteins) have been performed using benzoquinone, glutaraldehyde, and formaldehyde as oxidizing agents (see, for example, Non-Patent Document 1).
  • benzoquinone and aldehydes are known to be oxidizing agents, they have an odor, are highly irritating to the skin and mucous membranes, and pose a physical burden on workers and the environment. Become.
  • aldehydes are used, a longer reaction time is required, and the resulting large-diameter artificial polypeptide fibers are colored.
  • enzymatic reaction can be used to increase the diameter, so there is no need to use the above-described oxidizing agent, and the burden on workers and the environmental load can be reduced.
  • the high substrate specificity of the enzyme may reduce side reactions and reduce contamination.
  • the method according to the present embodiment may further comprise a step of preparing raw material fibers (thin-diameter artificial polypeptide fibers).
  • the raw fibers obtained by this step can be bundled and crosslinked by an enzymatic reaction.
  • a thin artificial polypeptide fiber obtained through a spinning process from an artificial polypeptide may be used as a raw material fiber.
  • the enzyme reacts with at least one of the raw material fiber and the binder to generate a reactive functional group, which is crosslinked by chemically bonding with the surrounding raw material fiber or binder.
  • a schematic diagram of the resulting artificial polypeptide fiber is shown in FIG. As shown in FIG. 1, raw material fibers 1 are bonded together via a binder 2 to form a single thick fiber 10 as a whole.
  • Raw fibers can be produced by a known spinning method. That is, for example, when producing a raw material fiber containing protein as a main component, first, a protein (for example, modified fibroin) produced according to the above-described method is added to dimethyl sulfoxide (DMSO), N,N-dimethylformamide ( DMF), formic acid, or hexafluoroisopropanol (HFIP), if necessary, together with an inorganic salt as a dissolution accelerator, are added and dissolved to prepare a dope solution. Then, using this dope solution, spinning is performed by a known spinning method such as wet spinning, dry spinning, dry-wet spinning, or melt spinning to obtain the desired raw material fiber. Preferred spinning methods include wet spinning or dry-wet spinning.
  • DMSO dimethyl sulfoxide
  • DMF N,N-dimethylformamide
  • HFIP hexafluoroisopropanol
  • Preferred spinning methods include wet spinning or dry-wet spinning
  • FIG. 7 is an explanatory diagram schematically showing an example of a spinning device for producing raw fibers.
  • a spinning device 10 shown in FIG. 7 is an example of a spinning device for dry-wet spinning, and includes an extrusion device 1 , an undrawn yarn producing device 2 , a wet-heat drawing device 3 , and a drying device 4 .
  • the dope liquid 6 stored in the storage tank 7 is pushed out from the mouthpiece 9 by the gear pump 8 .
  • the dope solution may be filled into a cylinder and pushed out through a nozzle using a syringe pump.
  • the extruded dope liquid 6 is supplied through the air gap 19 into the coagulation liquid 11 of the coagulation liquid bath 20, the solvent is removed, the protein is coagulated, and a fibrous coagulum is formed.
  • the fibrous coagulum is fed into hot water 12 in a drawing bath (washing bath) tank 21 and drawn.
  • the draw ratio is determined by the speed ratio between the supply nip roller 13 and the take-up nip roller 14 . After that, the drawn fibrous coagulate is supplied to the drying device 4 and dried in the yarn path 22 to obtain the raw material fibers 36 as the wound yarn 5 . 18a-18g are thread guides.
  • the coagulating liquid 11 may be any solvent that can remove the solvent, and examples thereof include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol and 2-propanol, and acetone.
  • the coagulation liquid 11 may contain water as appropriate.
  • the temperature of the coagulation liquid 11 is preferably 0 to 30.degree.
  • the extrusion rate is preferably 0.2 to 6.0 ml/hour, preferably 1.4 to 4.0 ml/hour. Time is more preferred.
  • the distance over which the coagulated protein passes through the coagulation liquid 11 should be sufficient for efficient removal of the solvent, for example, 200 to 500 mm. is.
  • the undrawn yarn take-up speed may be, for example, 1 to 20 m/min, preferably 1 to 3 m/min.
  • the residence time in the coagulation liquid 11 may be, for example, 0.01 to 3 minutes, preferably 0.05 to 0.15 minutes. Further, stretching (pre-stretching) may be performed in the coagulating liquid 11 .
  • the coagulation liquid bath 20 may be provided in multiple stages, and stretching may be performed in each stage or in a specific stage as required.
  • the drawing performed when obtaining the raw material fiber may be, for example, the pre-drawing performed in the coagulating liquid tank 20 and the wet-heat drawing performed in the drawing bath 21, as well as the dry-heat drawing.
  • Wet heat stretching can be performed in hot water, in a solution of hot water added with an organic solvent or the like, or in steam heating.
  • the temperature may be, for example, 50 to 90°C, preferably 75 to 85°C.
  • the undrawn yarn (or pre-drawn yarn) can be drawn, for example, 1 to 10 times, preferably 2 to 8 times.
  • Dry heat drawing can be performed using an electric tubular furnace, a dry heat plate, or the like.
  • the temperature may be, for example, 140°C to 270°C, preferably 160°C to 230°C.
  • the undrawn yarn (or pre-drawn yarn) can be drawn, for example, 0.5 to 8 times, preferably 1 to 4 times.
  • the wet heat drawing and the dry heat drawing may be performed independently, or they may be performed in multiple stages or in combination. That is, the first step drawing is performed by wet heat drawing, the second step drawing is performed by dry heat drawing, or the first step drawing is performed by wet heat drawing, the second step drawing is performed by wet heat drawing, and the third step drawing is performed by dry heat drawing.
  • wet heat stretching and dry heat stretching can be combined as appropriate.
  • the lower limit of the final draw ratio is preferably more than 1 times, 2 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times with respect to the undrawn yarn (or pre-drawn yarn). 7 times or more, 8 times or more, 9 times or more, and the upper limit is preferably 40 times or less, 30 times or less, 20 times or less, 15 times or less, 14 times or less, 13 times or less. , 12 times or less, 11 times or less, and 10 times or less.
  • the raw material fiber that repeatedly stretches and contracts in the wet state and the dry state described above is manufactured by, for example, shrinking the fiber obtained by spinning (that is, the fiber before contacting with water after spinning) with water.
  • the shrinking step may include, for example, a step of irreversibly shrinking the fibers produced by the above spinning method (fibers after spinning but before contact with water) by contacting them with water (contacting step).
  • the shrinking step may comprise, after the contacting step, drying the fibers to further shrink them (drying step).
  • the fiber diameter (cross-sectional diameter) of the raw material fiber may be, for example, 5 to 100 ⁇ m, 10 to 90 ⁇ m, 20 to 80 ⁇ m, 30 to 70 ⁇ m, or 40 to 60 ⁇ m.
  • a second embodiment of the invention is an artificial polypeptide fiber obtainable by the method according to the first embodiment.
  • raw material fibers 1 are bonded together via a binder 2 to form one thick fiber 10 as a whole.
  • the fiber diameter (cross-sectional diameter) of the artificial polypeptide fiber (large-diameter artificial polypeptide fiber) according to the present embodiment is, for example, 0.5 to 5.0 mm, 1.0 to 4.5 mm, 1.5 to 4.0 mm. 0 mm, 2.0-3.5 mm, or 2.5-3.0 mm.
  • the number of raw fibers constituting the artificial polypeptide fiber usually matches the number of raw fibers to be bundled, for example, 5 to 100, 10 to 90, 20 to 80, 30 to 70, or 40 to 60. It can be adjusted within the scope of the book.
  • the artificial polypeptide contained in the artificial polypeptide fiber according to the present embodiment preferably contains a structural protein, more preferably fibroin, and even more preferably spider silk fibroin.
  • a third embodiment of the present invention is an adhesive for bonding fibers containing an artificial polypeptide together, the adhesive comprising a binder and an enzyme that reacts with at least one of the artificial polypeptide and the binder. is.
  • the definition of the raw material fiber described in the first embodiment can be referred to. Also, the description of the first embodiment can be referred to for the binder and the enzyme.
  • the adhesive according to the present embodiment may be a combination of a first composition containing a binder and a second composition containing an enzyme, or a composition containing both a binder and an enzyme. good.
  • the former form is preferred when the binder is a reaction substrate for an enzyme.
  • composition constituting the adhesive according to the present embodiment contains solvents, excipients, buffers, stabilizers, preservatives, preservatives, physiological saline, etc. in addition to binders and/or enzymes. good too.
  • Solvents include dimethylsulfoxide (DMSO), diethylene glycol monoether, ethanol, methanol, isopropanol.
  • DMSO dimethylsulfoxide
  • excipients starch, dextrin, maltose, trehalose, lactose, D-glucose, sorbitol, D-mannitol, sucrose, glycerol and the like can be used.
  • Phosphate, citrate, acetate and the like can be used as buffers.
  • Propylene glycol, ascorbic acid and the like can be used as stabilizers.
  • Preservatives that can be used include phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, methylparaben, and the like. Ethanol, benzalkonium chloride, paraoxybenzoic acid, chlorobutanol, etc. can be used as antiseptics.
  • a nucleic acid encoding a protein with the designed amino acid sequence was synthesized.
  • An NdeI site was added to the 5' end of the nucleic acid, and an EcoRI site was added downstream of the termination codon.
  • These two types of nucleic acids were each cloned into a cloning vector (pUC118). Thereafter, the same nucleic acid was treated with restriction enzymes NdeI and EcoRI, cut out, and then recombined into the protein expression vector pET-22b(+) to obtain an expression vector.
  • the seed culture solution was added to a jar fermenter to which 500 mL of production medium (Table 5) was added so that the OD 600 was 0.05, and the transformed E. coli was inoculated.
  • the temperature of the culture solution was kept at 37° C. and the pH was constantly controlled to 6.9 for culturing. Also, the dissolved oxygen concentration in the culture solution was maintained at 20% of the dissolved oxygen saturation concentration.
  • the feed solution (glucose 455 g/1 L, Yeast Extract 120 g/1 L) was added at a rate of 1 mL/min.
  • the temperature of the culture solution was kept at 37° C. and the pH was constantly controlled to 6.9 for culturing.
  • the dissolved oxygen concentration in the culture medium was maintained at 20% of the dissolved oxygen saturation concentration, and culture was carried out for 20 hours.
  • 1 M isopropyl- ⁇ -thiogalactopyranoside (IPTG) was added to the culture solution to a final concentration of 1 mM to induce expression of the desired modified fibroin.
  • IPTG isopropyl- ⁇ -thiogalactopyranoside
  • the culture solution was centrifuged to collect the cells. SDS-PAGE was performed using the cells prepared from the culture solution before and after the addition of IPTG, and the expression of the desired modified fibroin was confirmed by the appearance of the desired modified fibroin size band depending on the addition of IPTG. bottom.
  • the precipitate after washing was suspended in 8M guanidine buffer (8M guanidine hydrochloride, 10mM sodium dihydrogen phosphate, 20mM NaCl, 1mM Tris-HCl, pH 7.0) to a concentration of 100mg/mL, and was incubated at 60°C for 30 minutes. Stir with a stirrer for 1 minute to dissolve. After dissolution, dialysis was performed with water using a dialysis tube (cellulose tube 36/32 manufactured by Sanko Junyaku Co., Ltd.). The white aggregated protein obtained after dialysis was recovered by centrifugation, water was removed with a freeze dryer, and a freeze-dried powder was recovered.
  • 8M guanidine buffer 8M guanidine hydrochloride, 10mM sodium dihydrogen phosphate, 20mM NaCl, 1mM Tris-HCl, pH 7.0
  • Nozzle hole diameter 0.3mm
  • Coagulation liquid 18% sodium sulfate aqueous solution
  • Temperature of coagulation liquid 50°C
  • [Preparation of binder solution] A 0.02 M sodium carbonate aqueous solution (400 mL) was added to silkworm cocoons (1 g), and the mixture was heated at 80 to 90° C. for 30 minutes or longer. The warmed liquid was filtered through a paper filter, washed with MilliQ water, and air-dried to obtain silk fibers. After adding 9.3 M lithium bromide aqueous solution (3 mL) to the obtained silk fibers (0.76 g), the mixture was heated at 60° C. for 5 hours or longer to completely dissolve the silk fibers. Insoluble materials were removed by centrifugation, and dialysis was repeated to exchange buffer 50 mM Tris-HCl buffer, pH 7.0, 150 mM sodium chloride.
  • the buffer was replaced with a 50 mM Tris-hydrochloride buffer, pH 7.0, 150 mM sodium chloride buffer to obtain a silk fibroin solution.
  • the obtained silk fibroin solution was divided, and various enzymes were added as shown in Table 6 so as to have a predetermined concentration to obtain binder solutions E1 to E3.
  • solutions NE1 (no binder or enzyme), NE2 (no enzyme), NE3 (no binder) and NE4 (no binder) were prepared.
  • laccase manufactured by Amano Enzyme Co., Ltd.
  • bilirubin oxidase manufactured by Amano Enzyme Co., Ltd.
  • glucose oxidase manufactured by Amano Enzyme Co., Ltd.
  • peroxidase manufactured by Amano Enzyme Co., Ltd.
  • Photograph 1 is a photograph showing how raw fibers (PRT918) are bundled.
  • Photo 2 shows a state in which the bundled raw material fibers are placed in a pipette and one opening is closed with a seal.
  • Photograph 3 is a photograph showing a state in which the other opening is closed with a seal.
  • Photograph 4 is a photograph showing the obtained artificial polypeptide fiber having a large diameter. All of the thick artificial polypeptide fibers had a thickness of 1.6 mm.
  • a raw material fiber (PRT918) bundled with 20 to 25 fibers was used as Comparative Example 3.
  • Table 8 shows the results. In the physical property test, Examples 1 to 3 broke at once as the tensile strain was increased, but Comparative Examples 1 to 3 broke stepwise several times.
  • gelatin solution 0.5 mL was placed in a glass test tube, and laccase (manufactured by Amano Enzyme Co., Ltd.) was added as shown in Table 9 to obtain a binder solution E4.
  • binder solution The silk fibroin solutions obtained in the same manner as described above were divided, and various enzymes were added to give predetermined concentrations as shown in Table 10 to obtain binder solutions E5 to E8. For comparison, solutions NE6 (no enzyme) and NE7 (no enzyme) were prepared.
  • Table 12 shows the results. Examples 5-8 had a stress greater than that of Comparative Example 3 by 0.1 gf/den or more, and all fibers remained fused after the washing test.
  • a binder solution E9 was obtained by adding a 50 mM Tris-HCl buffer, pH 7.0, 150 mM sodium chloride buffer to commercially available sugar beet-derived pectin as shown in Table 13 instead of silk fibroin.
  • Example 15 shows the results. In Example 9, all fibers remained fused after the wash test, but in Comparative Example 6, no adhesive effect was observed.
  • Binder solutions E9 to E11 were obtained by adding a buffer of 50 mM Tris-HCl buffer, pH 7.0, 150 mM sodium chloride to chemical oxidants (glutaraldehyde, formaldehyde) as shown in Table 16 instead of the enzyme.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Textile Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé de fabrication d'une fibre polypeptidique artificielle, le procédé comprenant : une étape de mise en faisceau d'une pluralité de fibres de matière première contenant un polypeptide artificiel; et une étape pour amener un faisceau obtenu de fibres de matière première en contact avec une composition contenant un liant et une enzyme.
PCT/JP2022/034270 2021-09-13 2022-09-13 Fibre polypeptidique artificielle de grand diamètre, son procédé de fabrication et adhésif WO2023038154A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023547165A JPWO2023038154A1 (fr) 2021-09-13 2022-09-13

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-148845 2021-09-13
JP2021148845 2021-09-13

Publications (1)

Publication Number Publication Date
WO2023038154A1 true WO2023038154A1 (fr) 2023-03-16

Family

ID=85506544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/034270 WO2023038154A1 (fr) 2021-09-13 2022-09-13 Fibre polypeptidique artificielle de grand diamètre, son procédé de fabrication et adhésif

Country Status (2)

Country Link
JP (1) JPWO2023038154A1 (fr)
WO (1) WO2023038154A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5581548A (en) * 1978-12-13 1980-06-19 Kuraray Co Ltd Bundle of fine fiber and their preparation
CN103088503A (zh) * 2013-01-10 2013-05-08 韩仕银 胶原纤维束的改性方法
JP2020122249A (ja) * 2019-01-31 2020-08-13 国立大学法人信州大学 フィブロイン繊維の製造方法及びフィブロイン溶液

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5581548A (en) * 1978-12-13 1980-06-19 Kuraray Co Ltd Bundle of fine fiber and their preparation
CN103088503A (zh) * 2013-01-10 2013-05-08 韩仕银 胶原纤维束的改性方法
JP2020122249A (ja) * 2019-01-31 2020-08-13 国立大学法人信州大学 フィブロイン繊維の製造方法及びフィブロイン溶液

Also Published As

Publication number Publication date
JPWO2023038154A1 (fr) 2023-03-16

Similar Documents

Publication Publication Date Title
JP6736802B2 (ja) 改変フィブロイン
JP6736801B2 (ja) 改変フィブロイン
JP7048058B2 (ja) 改変フィブロイン
JP6959482B2 (ja) 成形体及びその製造方法、並びに成形体のタフネスを向上させる方法
JP7133810B2 (ja) 改変フィブロイン
WO2018043698A1 (fr) Corps moulé et procédé de production de corps moulé
WO2023038154A1 (fr) Fibre polypeptidique artificielle de grand diamètre, son procédé de fabrication et adhésif
JP2022162038A (ja) 合成高分子及びその製造方法、成形材料、並びに、成形体
JP2020120642A (ja) 改変フィブロイン繊維の製造方法及びタンパク質溶液
WO2019151432A1 (fr) Procédé de préparation d'une fibre protéinique frisée d'adhérence à l'huile
WO2021015153A1 (fr) Fibroïne modifiée
WO2020145363A1 (fr) Fibroïne modifiée
WO2019146765A1 (fr) Matériau pour corps moulé contenant une protéine, corps moulé contenant une protéine et procédé de production de corps moulé contenant une protéine
JP2020120643A (ja) 改変フィブロイン繊維の製造方法及びタンパク質溶液
JP2021095346A (ja) 改変フィブロイン架橋体を製造する方法
JP2024020557A (ja) 改変フィブロイン
WO2019131924A1 (fr) Corps moulé et procédé de production de corps moulé
WO2019117296A1 (fr) Méthode de production d'un produit moulé et produit moulé
JP2021054751A (ja) 構造タンパク質成形体の製造方法
JP2020055762A (ja) モールド成形体の製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22867475

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023547165

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE